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ABSTRACT
Structural Studies of the Catalytic and Regulatory Mechanisms of Phenylalanine
Hydroxylase. (August 2010)
Jun Li, B.S., Peking University Health Science Center
Co-Chairs of Advisory Committee: Dr. Paul F. Fitzpatrick
Dr. Gregory Reinhart
The catalytic and regulatory mechanisms of phenylalanine hydroxylase were
investigated by structural studies of in this research. Phenylalanine hydroxylase (PheH)
hydroxylates phenylalanine to produce tyrosine using tetrahydrobiopterin (BH4) and
oxygen. The three ligands to the iron, His285, His290, and Glu330, were mutated to
glutamine, glutamate, and histidine. All the mutants had low but measurable activity.
Mutation of Glu330 had the greatest effect on activity and mutation of His290 the least.
All the mutations resulted in an excess of tetrahydropterin oxidized relative to tyrosine
formation, with mutation of His285 having the greatest effect on the coupling of the two
partial reactions. All the mutants greatly decreased the affinity for iron, with mutation of
Glu330 the most deleterious. The results complement previous results with tyrosine
hydroxylase in establishing the plasticity of the individual iron ligands in this enzyme
family.
Hydrogen/deuterium exchange and mass spectrometry showed that peptides lying
in the interface between the regulatory and catalytic domains display large increases of
deuterium incorporation in the presence of phenylalanine. However, the effects of
iv
phenylalanine on a mutant enzyme lacking the regulatory domain are limited to peptides
surrounding the binding site of phenylalanine. These results support the autoinhibitory
function of the N-terminus of PheH. No peptides show a changed deuterium
incorporation pattern in the presence of BH4, suggesting that BH4 binding does not
change the structure significantly from the resting form. In phosphorylated PheH, three
peptides show a deuterium incorporation pattern similar to that of unphosphorylated
PheH plus phenylalanine, while the other peptides sensitive to phenylalanine binding in
unphosphorylated PheH show the same pattern as that of unphosphorylated PheH
without phenylalanine. Therefore, the conformational changes induced by
phosphorylation are similar to but not identical to those associated with phenylalanine
activation.
The isolated regulatory domain (PheH1-117) was expressed and purified using a Q-
Sepharose column followed by a gel filtration column. Analytical gel filtration shows
that PheH1-117 exists as a dimer in solution. In the presence of phenylalanine, the
retention time of PheH1-117 is significantly changed. The 1H-15N NMR spectra of PheH1-
117 show that the cross-peaks of several residues are altered in the presence of
phenylalanine. These results support the existence of a regulatory binding site for
phenylalanine in the regulatory domain of PheH.
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1CHAPTER I
GENERAL INTRODUCTION
Phenylalanine Hydroxylase
Overview of phenylalanine hydroxylase
Human phenylalanine hydroxylase (hPheH) converts the essential amino acid L-
phenylalanine into L-tyrosine using (6R)-l-erythro-5,6,7,8-tetrahydrobiopterin (BH4) and
molecular oxygen. The catalysis by this iron dependent non-heme monooxygenase is the
major pathway for catabolic degradation of dietary phenylalanine and accounts for 75%
of the disposal of phenylalanine. Mutations in the hPheH gene lead to altered kinetic
properties and/or reduced in vivo stability of the enzyme associated with the autosomal
recessive metabolic disorder phenylketonuria (PKU). Phenylalanine hydroxylase (PheH)
is coded for by the PAH gene, found on human chromosome 12 (1). So far, over 400
mutations in PheH gene have been associated with PKU or a milder form of
hyperphenylalaninemia (HPA) (2).
Human PheH mostly exists in the liver as a pH-dependent equilibrium of
homodimer and homotetramer (3-5). PheH belongs to the aromatic amino acid
hydroxylase family along with tyrosine hydroxylase (TyrH) and tryptophan hydroxylase
(TrpH). Like TyrH and TrpH, each monomer of PheH is composed of three domains: an
N-terminal regulatory domain, a catalytic domain and a C-terminal tetramerization
domain. Each subunit of PheH is near 52 kD. PheH requires ferrous iron atom for
____________
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2reaction, while the enzyme is purified with ferric iron bound in the active site (3).
The earliest report of PheH was in 1913, when the conversion of phenylalanine to
tyrosine was demonstrated through in vitro experiments (4). About forty years later,
scientists began to actually characterize the enzyme (4). The early work provided
evidence that rat liver contains a hydroxylation system that was later identified as PheH
(4). PheH is widely distributed in animal tissues such as heart, spleen, brain, thyroid,
kidney, rabbit muscle, and pancreas.
Structure of phenylalanine hydroxylase
Overall structure of phenylalanine hydroxylase
Because of the difficulty of crystallizing full-length PheH, there are no full-length
tetrameric structures for PheH. The crystal structure of the hPheH catalytic domain with
no ligand has been determined (PDB 1PAH) (5). An N-terminal truncated form of PAH
including the catalytic and tetramerization domains (residues 118–452) was crystallized
as a dimer (PDB 2PAH) (6). The structures of the catalytic domain of hPheH (residues
102-427) were also determined in the presence of ferric iron and cofactor or the
inhibitors L-epinephrine (PDB 3PAH), L-norepinephrine (PDB 4PAH), dopamine (PDB
5PAH) and L-DOPA (PDB 6PAH) (7). Two important crystal structures of rat PheH
including the regulatory and catalytic domains (∆COOH430) were determined in the
phosphorylated and non-phosphorylated states with ferric iron (PDB 1PHZ and 2PHM)
(8). They provided the structure of the regulatory domain for the first time, although the
N-terminal first 18 residues were missing. The structure of the catalytic domain of
hPheH (residues 118-424) in complex with ferric iron and the oxidized form of cofactor
37, 8-dihydro-L-biopterin, BH2 has also been determined (PDB 1DMW) (9). The
structures of the catalytic domain of hPheH in the presence of ferrous iron atom alone
(PDB 1J8T) (10), in the binary complex with BH4 (PDB 1J8U)(10), and in ternary
complex with BH4 and 3-(2-thienyl)-l-alanine (THA) (PDB 1KW0) or L-norleucine
(NLE) (PDB 1MMT) were also solved (11). Although there is no full length crystal
structure, a composite full-length structural model can be constructed by superimposing
the catalytic domains of a dimeric form containing the regulatory and catalytic domains
and a tetrameric form containing the catalytic and tetramerization domains (Figure 1.1)
(12).
Regulatory domain
The regulatory domain of PheH is an α-β sandwich, forming an interlocking double
βαβ motif (βαββαβ) motif. This domain is composed of a four-stranded antiparallel β-
sheet flanked on one side by two short α-helices and on the other side by the segments of
118-131 and 409-422 of the catalytic domain. The N-terminal sequence (residues 19-33)
extends over the active site in the catalytic domain, contacting residues 130-136, 249-
252, 315-326 and 376-379 (8). Bacterial PheHs do not have a regulatory domain.
Eukaryotic PheH regulatory domains share low similarities with those of TyrH and TrpH.
The best match instead is the regulatory domain of phosphoglycerate dehydrogenase
(PGDH). The regulatory domain of PheH also resembles the regulatory domains of two
other enzymes: threonine deaminase (TD) and aspartate carbamoyltransferase (ATCase)
(8). All three enzymes sharing structural similarity with the regulatory domain of PheH
4Figure 1.1. The crystal structure of full-length phenylalanine hydroxylase (Protein Data
Bank codes 2PAH and 2PHM). The iron atom is shown as a red sphere. The regulatory
domain (1-142), catalytic domain (142-427) and tetramerization domain (428-453) are
indicated in green, yellow and cyan.
5are feedback allosteric enzymes. The core of the regulatory domain of PheH is far from
the active site, but the N-terminus extends from the core of the regulatory domain to the
active site pocket (Figure 1.2). The N-terminal 18 residues including the phosphorylation
site Ser16 are missing from the structure of the regulatory domain of both
dephosphorylated and phosphorylated ∆COOH24 PheH, suggesting that this region is
highly mobile. No structural difference is observed between dephosphorylated and
phosphorylated ∆COOH24 PheH.
Catalytic domain: the active site and binding sites for iron and substrates
The PheH monomer is composed of 13 α-helices and 8 β-strands, with approximate
dimensions of 50 Å × 45 Å × 45 Å. The catalytic domain is a novel basket-like
arrangement of helices and loops with an open active-site that is approximately 13 Å ×
13 Å wide 10 Å deep. The majority of the residues lining the active site are hydrophobic
residues except for three charged glutamates, two histidines, and a tyrosine. Covering the
entrance of the active site from the channel direction is a short loop (residues 378−381)
(5).
The Fe(III) atom is located at the bottom of the active site pocket, 10 Ǻ below the
surface of protein (5). The iron atom is coordinated to His285 (N···Fe, 2.2 Å), His290
(N···Fe, 2.2 Å) and one oxygen atom in Glu330 (O···Fe, 2.2 Å). Three water molecules
are also coordinated to the iron (H2O(1)·· ·Fe, 2.3 Å; H2O(2)· ··Fe, 2.1 Å; H2O(3)· ··Fe,
2.3 Å). In the absence of phenylalanine, the iron ligands are arranged in an octahedral
geometry (Figure 1.3). In the presence of phenylalanine, the iron is 5-coordinate, with
Glu330 binding the iron atom in a bidentate fashion (13).
6Figure 1.2. The position of the N-terminal sequence (residues 19-33) in PheH. The
structure of PheH, constructed as in Figure 1.1, is shown in surface format except that
residues 19−33 are shown as green sticks. The iron atom is displayed as a red sphere.
7Figure 1.3. The iron and tetrahydrobiopterin binding sites of PheH. The structures are
from the PDB files 1J8U. The iron atom is shown as a yellow sphere, and the three water
molecules involved in coordination are shown as red spheres.
Gly247
Leu248
Leu249
Ser250
Ser251
BH4
Glu286
His290
Glu330
His285
8The loop residues 247-251 form direct hydrogen bonds to the BH4. In the structure
of the ternary complex, the BH4 C3′ forms hydrophobic contacts with Leu255 Cδ1
(3.6 Å), Ser 251 Cα (3.8 Å) and Phe254 Cδ2 (3.8 Å), while the BH4 C8a and C7 form
contacts with Leu248 Cδ1 (Figure 1.3) (13). Glu286 forms hydrogen bonds directly to N3
and O4 of BH4; in the structure of binary complex this residue forms two similar but
water-mediated hydrogen bonds to BH4 and a 2.7 Å hydrogen bond to one of the water
molecules coordinated with the iron atom (10). Phe254 is close to the iron, at the edge of
the proposed BH4 binding site. The aromatic ring of Phe254 may form a π-stacking
interaction with the pterin ring (5).
There is no crystal structure of PheH in complex with L-phenylalanine, but there is
one of the ternary complex of the catalytic domain of PheH with BH4 and 3-(2-thienyl)-
l-alanine (THA), an analogue of phenylalanine. Because THA binds competitively with
L-phe (14), the current structure with THA can help model the binding site for
phenylalanine. A modeled phenylalanine is directly hydrogen-bonded to Arg270, Thr278
and Ser349. It forms water-mediated hydrogen bonds to Tyr277, Gly346, Ser350 and
Glu353. In addition, it forms hydrophobic contacts with His285 and Phe331 (Figure 1.4)
(13).
9Figure 1.4. THA-binding ligands in the ternary complex of PheH (PDB file 1MMK).
Arg270, Thr278 and Ser349 are directly hydrogen-bonded to THA. Tyr277, Gly346,
Ser350 and Glu353 form water-mediated hydrogen bonds to THA. Two water molecules
are shown as red spheres. His285 and Phe331 form hydrophobic contacts with THA that
are not shown here.
THA
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Catecholamine inhibitors directly coordinate to the metal center, forming blue-
green ligand-to-metal charge-transfer complexes for hTyrH (15, 16). Competitive
inhibition by catecholamines versus BH4 was observed for PheH (17, 18). The overall
structures of hPheH in complex with L-DOPA, dopamine, noradrenaline, and adrenaline
are very similar to each other and to the uncomplexed enzyme. These structures clearly
show that the inhibitors bind to the iron atom in a bidentate coordination of the two
hydroxyl groups by replacing two iron-bound water molecules (distances of 2.0−2.1 Å).
In addition to the bidentate coordination to the iron center, the catecholamines form
hydrogen bonds with Glu330 and Tyr325 at the active site (distances of 2.6 Å between
O2 and Tyr325 OH and Glu330 Oε2). These two residues may be involved in the
stabilization of the relatively high-affinity binding ([S]0.5 < 1 μM) of the amines at
neutral pH. The residues are highly conserved in the aromatic amino acid hydroxylases
(7).
Tetramerization domain
Full-length PheH has been described as existing as both a tetramer and dimer in a
pH-dependent equilibrium, and possibly as some monomer (16). Lowering the pH or
binding of phenylalanine shifts the equilibrium toward the tetrameric form of PheH (17).
The tetramerization domain is composed of a C-terminal “arm” containing two anti-
parallel β-strands, forming a β-ribbon, and a 40 Å long α-helix. The C-terminal arm
extends over a neighboring monomer bringing the four helices (one from each monomer)
into a tightly packed anti-parallel coiled-coil motif in the center of the structure. The
tetramer is formed by two conformationally different dimers resulting in a distortion of
11
the 222 symmetry, caused by the occurrence of two alternate conformations of the hinge
region leading to the coiled-coil helix (6).
Regulation
Given the fact that there is enough PheH in liver to remove phenylalanine rapidly
and completely if the enzyme is fully activated, it is important that PheH be tightly
controlled by a variety of mechanisms. The major mechanisms are activation by
phenylalanine, inhibition by BH4, and additional activation by phosphorylation (18).
There are other regulatory mechanisms, including transcriptional regulation,
chymotrypsin proteolysis and other activators such as lysolecithin.
Substrate-induced activation
Activation by the substrate phenylalanine is considered the key regulatory event. If
the enzymatic reaction is started by adding enzyme, a lag in the rate of tyrosine
formation is observed. Pretreatment with phenylalanine or lysolecithin can remove the
lag, but treatment with BH4 or 6-methyl-tetrahydropterin (6MePH4) increases it (19).
Activation of full-length PheH by phenylalanine is a reversible allosteric regulation with
positive cooperativity. The activity of PheH manifests a sigmoidal dependence on the
phenylalanine concentration (19). It has been postulated that there exist two
phenylalanine-binding sites: a regulatory site and a catalytic site (19, 20). The regulatory
binding site is responsible for the allosteric cooperativity. There is no crystal structure of
PheH with phenylalanine that can directly support this two binding site model. However,
there is some indirect evidence. The native PheH binds 1.5 equivalents of phenylalanine
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per subunit with strong positive cooperativity but the thiol-modified enzyme can only
bind one equivalent without cooperativity (20).
Activation of PheH by phenylalanine can directly induce conformational changes
detectable by UV spectroscopy (21) and by an increase of the surface hydrophobicity of
PheH in the presence of phenylalanine (22). The binding of phenylalanine induces both
local and global conformational changes, based on the comparison of crystal structures
of PheH. The structure of the ternary enzyme complex is slightly smaller than the binary
or ligand-free PheH structure because of more compact packing. A prominent local
structural change in the presence of phenylalanine is the manner in which the iron atom
binds at the center of active site. As mentioned above, in the absence of phenylalanine,
the iron atom is coordinated by six ligands: three amino acid residues and three water
molecules. Glu330 has a monodentate interaction with iron atom. In the presence of
phenylalanine, the iron atom ligands are three amino acid ligands and a water molecule,
and Glu330 has a bidentate interaction. Part of loop 131-155 is refolded in the presence
of phenylalanine, resulting in substantial displacement of Tyr138. The hydroxyl of this
residue moves from an exposed position on the surface to the active site, where the
phenol ring packs between Leu248 and Val379 forming a hydrophobic pocket (Figure
1.5). In addition to the large motion of loop 131-155, loop 247-252 moves 2.6 Å closer
to the iron atom in the presence of phenylalanine.
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Figure 1.5. Movement of the 131-146 loop in PheH upon binding of β-thienylalanine to
the tetrahydrobiopterin-bound enzyme. The loop in green with Tyr138 in magenta is
from the binary complex (PDB file 1J8U); the loop in cyan with Tyr138 in dark blue is
from the ternary complex (PDB file 1KWO). The iron atom is shown as a brown sphere.
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The structures of phosphorylated and dephosphorylated PheH provide more
information about the mechanism of phenylalanine-induced activation (8). The N-
terminal sequence 19-33, the so-called N-terminal autoregulatory sequence (NARS),
extends across the active site, contacting residues 130-136, 249-252, 315-326 and 376-
379. The NARS is proposed to cover the entrance of the active site, leaving a narrow
access for substrates. Later research showed that a mutant PheH lacking the NARS does
not require activation by phenylalanine and is not inhibited by BH4, supporting the
proposed function of the NARS (23). A similar activation can be achieved by the
modification of Cys237, which is located on the surface, near the interface of the
regulatory and catalytic domains. It is possible that phenylalanine binding induces
conformational changes that alter the relative orientation of the regulatory and catalytic
domains, exposing the interface region including Cys237 (8).
Activation by phosphorylation
PheH can be phosphorylated at Ser16, a physiologically relevant post-translational
modification (24). Phosphorylation of PheH is by cyclic AMP-dependent protein kinase
(PKA) (25). A calmodulin-dependent protein kinase (CaM-PK) can phosphorylate PheH
at the same site as PKA (26). There is controversy about the effect of phosphorylation on
the kinetic characteristics of PheH. The phosphorylated PheH is reported to be two to
four fold more active than the dephosphorylated enzyme in the presence of BH4, with
little or no change in the Km for BH4 or phenylalanine (25). It also has been reported that
phosphorylation does not affect the Vmax but merely decreases the concentration of
phenylalanine needed to activate PheH (27, 28). The concentration of phenylalanine
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required for the half-maximal activation of the phosphorylated enzyme is 30 to 40% less
compared to the dephosphorylated protein (28). Phenylalanine makes PheH more readily
phosphorylated by PKA (28). The combined effects of these two regulatory mechanisms
in vivo could increase the efficiency of the regulation of PheH by phenylalanine.
Comparison between the crystal structures of phosphorylated and dephosphorylated
PheH indicates that phosphorylation has no major structural effects in the absence of
phenylalanine, consistent with the proposal that phenylalanine and phosphorylation act
in concert to activate the enzyme through a combination of intrasteric and possibly
allosteric mechanisms (8).
The phosphorylation site, Ser16, located in the N-terminal region beyond the NARS
(residues 19-33), is missing in the crystal structures of phosphorylated and
dephosphorylated PheH. Mutation of Ser16 to glutamate has the same effect on activity
as phosphorylation (29), while mutation of Ser16 to alanine results in a mutant protein
with the same characteristics as the dephosphorylated PheH. These results indicate that
activation of PheH by phosphorylation is due to the introduction of a negative charge,
suggesting the involvement of electrostatic interactions (30). The negative charge on
Ser16 allows the NARS (residues 19-33) to make electrostatic interactions with the
catalytic domain. In the absence of phenylalanine, the NARS covers the entrance into the
active site leaving a narrow access for substrate. Incubation with phenylalanine causes a
relative rotation of the regulatory and catalytic domains, which could be stabilized by
phosphorylation on Ser 16, resulting in the displacement of the NARS from the entrance
of the active site (8).
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Inhibitors
PheH is inhibited by catecholamines, similarly to the other aromatic amino acid
hydroxylases (18). The physiological cofactor of PheH, BH4, is reported to inhibit the
activation by phenylalanine. The lag observed when starting the reaction by adding
enzyme is increased if the enzyme is treated with BH4 (19). BH4 is also reported to
inhibit activation by lysolecithin (31). BH4 protects native PheH from cleavage between
the regulatory and catalytic domains by chymotrypsin, while the regulatory domain is
cleaved from the catalytic domain in the absence of BH4 (32). Phosphorylation of PheH
by PKA is inhibited by BH4, in contrast to the effect of phenylalanine (28).
Other activation
Proteolysis of PheH by chymotrypsin increases the measured Vmax value.
Chymotrypsin reduces the size of PheH from 52 kDa to 36 kDa in the presence of BH4
by removing an N-terminal 11 kDa fragment, and a C-terminal 5 kDa fragment. The 36
kDa domain that remains is 30-fold more active than native PheH when assayed in the
presence of BH4, suggesting that the N-terminal 11 kDa region may mediate PheH
inhibition (32).
Treatment of rat PheH with lysolecithin or a thiol-modifying reagent such as N-
ethylmaleimide has a similar activation effect and exposes a single thiol group (20, 33).
These results suggest the two treatments may result in similar conformational changes.
Activation of PheH by thiol-modification results in up to 82% of the activity found with
phenylalanine-activated enzyme. The modified cysteine was identified as Cys237 (34).
Cys237, localized on the surface of the catalytic domain, is conserved in rat, human,
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mouse and Drosophila melanogaster PheHs. The mutant C237D-hPAH has higher basal
activity than phenylalanine-activated hPAH (35). Cys237 is spatially close to residues in
the oligomerization and regulatory domains of an adjacent subunit in the dimer, notably
Arg68. Arg68 is in loop 68-75 in the regulatory domain and also has contacts with
residues from the same subunit. The mutations C237D, R68A, and C237A result in
increases in the basal activity and affinity for phenylalanine, while the mutant C237R
PheH shows a reduced affinity for the substrate and elimination of positive cooperativity.
These activating mutations induce a series of conformational changes, including the
displacement of the NARS from the active site, the domain movements around the hinge
region Arg111−Thr117, and the rearrangement of loop 68−75 (36). These
conformational changes seem to also occur during activation of PheH by phenylalanine,
supporting the proposal that phenylalanine-induced activation also occurs through a
combination of sequential conformational changes.
The activity of PheH is also under transcriptional regulation, though little is known
about this. The 5’ region of gene for mammalian PheH lacks a proximal TATA box but
contains various sequences that can interact with multiple transcriptional factors (37).
The level of PheH in the liver is controlled at the transcriptional level by glucocorticoids,
which interact with a partial glucocorticoid response element (37).
Model of regulation mechanism
Based on the regulatory characteristics of phenylalanine and BH4, Shiman and his
colleagues proposed a model for the mechanism of regulation of PheH (Scheme 1.1) (38,
39). Purified PheH is proposed to be in an inactive form, Ei; binding of phenylalanine,
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converts the enzyme into an active form, Ea; binding of cofactor BH4, traps the enzyme
in the inactive BH4·enzyme complex and blocks phenylalanine activation. This model
predicts that conformational changes accompany binding of both amino acid and
cofactor, in agreement with the crystal structures.
Scheme 1.1. Model for regulation of PheH.
PKU and PKU therapy
Phenylalanine is an essential amino acid in the diet. PheH catalyzes the
hydroxylation of phenylalanine and produces tyrosine. As an aromatic amino acid,
phenylalanine, tyrosine and tryptophan are not only constituents of proteins, but also
the precursors of monoamine neurotransmitters, serotonin and the catecholamines
(dopamine, norepinephrine and epinephrine). Most dietary phenylalanine is
hydroxylated to tyrosine. Defects in the function of PheH result in high-level
accumulation of phenylalanine in blood. The high concentration of phenylalanine in
blood has a toxic effect on cognitive development (40). Excess phenylalanine is excreted
through the urinary system as intact phenylalanine or as phenylpyruvic acid (41).
A deficiency of phenylalanine hydroxylase due to mutations in the PheH gene is the
most common cause of the human disease phenylketonuria (PKU). PKU is an autosomal
recessive disease; the most common symptoms are high blood serum levels of
phenylalanine, lighter skin and hair pigmentation, a 'mousy' odor and mental retardation
(42). Ledley et al. (43) found no detectable phenylalanine hydroxylase enzymatic
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activity or immunoreactive protein in the liver of a fetus aborted after prenatal DNA
diagnosis of PKU, while both were found in control specimens of similar gestational age.
The size and the amount of the PheH mRNA were normal, suggesting that the mutations
affected the translation or stability of the protein (43).
The most important thing learned from the study of PKU pathogenesis is that the
treatment of PKU must reduce the phenylalanine content in blood. Traditional treatment
of PKU includes restriction of dietary phenylalanine and adequate intake of tyrosine (44).
Injection of phenylalanine ammonia-lyase (PAL), a recombinantly produced
phenylalanine metabolizing enzyme, can help clear the excess phenylalanine from the
circulation (45). For a subset of PKU patients, oral administration of sapropterin
dihydrochloride, a synthetic form of BH4, can reduce blood phenylalanine levels (46).
Patients with mutations in the regulatory domain often respond to BH4 (47). PheH is a
liver enzyme; therefore liver transplant is another potential treatment of PKU. However,
the life-long need for immunosupression due to transplantation reduces the quality of life.
Liver repopulation is an alternative method that might avoid the suffering of long-term
immunosupression. This method attempts to replace PheH-deficient hepatocytes with
healthy cells with PheH activity. These cells could be fully differentiated hepatocytes
from a healthy donor or embryonic stem cells. Like liver transplantation, this treatment
method is also limited by the scarcity of donors. Although still under research in the
laboratory, gene therapy is a promising strategy for PKU. This method attempts to
recover PheH activity by transferring PheH cDNA into the livers of a PKU patient. Most
published experiments of gene therapy for PKU use recombinant viral vectors (48, 49).
20
This method avoids an immune response but is limited by the low rate of cell
transduction and inefficient expression. Much work remains before gene therapy can be
applied in the clinic safely.
C. violaceum PheH
PheH is also present in bacteria. Only the PheH from Chromabacterium violaceum
has been characterized. C. violaceum PheH has many characteristics similar to
mammalian liver PheH. This bacterial enzyme is a monomeric enzyme (33 kD) (50),
while mammalian PheH is a mixture of dimer and tetramer. The primary structure of C.
violaceum PheH is 24% identical to rat and human PheH and 11% identical to
eukaryotic TyrH and TrpH (50). In contrast to the complex composition of three
domains in mammalian PheH, C. violaceum PheH has only one domain, corresponding
to the catalytic domain of mammalian PheH. The complex regulatory behaviors found
with the mammalian PheH have not been reported, making C. violaceum PheH a model
to study the activity without inference from regulation.
There are conflicting evidences reported in literatures on the metal requirement of
C. violaceum PheH. It was first described as a Cu2+-dependent enzyme (51). It was
subsequently reported to be a metal-independent enzyme (52). Finally, biochemical
studies showed that the Fe2+-dependent enzyme was the active form, and copper-
substituted C. violaceum PheH has no L-phenylalanine hydroxylation activity (53).
The kinetic mechanism of recombinant C. violaceum PheH was reported as a
sequentially ordered mechanism. The enzyme binds pterin first reversibly, followed by
reversible binding of amino acid and finally oxygen. No product is released before all
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three reactants bind (54). This mechanism is different from that of TyrH (55, 56). For rat
TyrH, the amino acid is believed to bind last.
The activity of C. violaceum PheH is the highest among all forms of PheH known.
C. violaceum PheH is ten-fold as active as the regulatory and tetramerization domain-
truncated human PheH (57). The isotope effects on the initial hydroxylation, subsequent
tautomerization step and benzylic hydroxylation for C. violaceum PheH are close to
those of the catalytic domain of eukaryotic PheH, suggesting the reactivities of the
prokaryotic and eukaryotic hydroxylases are similar (58).
Various crystal structures of Fe2+-dependent C. violaceum PheH including the Fe-
free, Fe(III)-bound and Fe(III) plus 7,8-BH2-bound have been determined (59). The
structure of C. violaceum PheH resembles the catalytic domains of human PheH and rat
TyrH. However, the N-terminal and C-terminal residues of C. violaceum PheH adopt
different folds from those of human PheH and rat TyrH. The active sites of C. violaceum
PheH and human PheH are similar. As in human PheH, the iron atom in the structure of
C. violaceum PheH coordinates with two histidine residues (His138 and His143) and one
glutamate residue (Glu184), forming an approximate octahedral coordination geometry
together with two water molecules. Glu184 coordinates with the iron atom in a bidentate
fashion in both the Fe(III)-bound and Fe(III) plus 7,8-BH2 structures, whereas it is
monodetate in the human PheH Fe(III) plus 7,8-BH2 form structure. The pterin-binding
loop 245-250 in human PheH moves toward the iron atom upon pterin binding. However,
the corresponding loop 98-103 in C. violaceum PheH only shows a minor
conformational change. The N-terminal regions of the three forms of C. violaceum PheH
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are completely different from those of hPheH and rat TyrH. The lack of the NARS and
other residues interacting with the active site makes the active site of C. violaceum PheH
more accessible to solvent. The C-terminus of C. violaceum PheH adopts a different
secondary structure from the C-termini of hPheH and rat PheH that form long alpha
helices for dimer or tetramer formation. The ten-fold higher specific activity of C.
violaceum PheH, compared to hPheH, may result from its more solvent accessible active
site, differential placement of the pterin binding loop, or the lack of the NARS. C.
violaceum PheH lacks many of mobility-restricting interactions that are seen in hPheH;
hence, the flexibility of the structure of C. violaceum PheH increases, resulting in more
catalytic efficiency.
Aromatic amino acid hydroxylase family
PheH belongs to the small enzyme family of aromatic amino acid hydroxylases that
includes two other members: tyrosine hydroxylase (TyrH) and tryptophan hydroxylase
(TrpH). The three enzymes are all homotetramers, and each monomer is composed of an
N-terminal regulatory domain (PheH 1-117; TyrH 1-164; TrpH 1-105), a catalytic
domain (PheH 118-410; TyrH 165-455; TrpH 105-401) and a C-terminal tetramerization
domain (PheH 411-453; TyrH 456-498; TrpH 402-444). Each monomer binds an iron
atom at the center of the catalytic domain. The catalytic domains of the three rat
enzymes are 52% identical, while the identity of the regulatory domains is less than 14%
(60).
Phenylalanine catabolism is a necessary metabolic pathway for emerging life forms
before neurotransmitter synthesis. Phenylalanine hydroxylation is ancestral
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phylogenetically, and PheH is close to the precursor of the aromatic amino acid
hydroxylase family (61). It is estimated that the gene for TyrH deviated from the
ancestral PheH about 750 million years ago and the gene for TrpH 600 million years ago,
explaining why TyrH alone acquired the ability to hydroxylate tyrosine (62).
Tyrosine Hydroxylase
Overview of tyrosine hydroxylase
Tyrosine hydroxylase (TyrH) is another well-studied member of aromatic amino
acid hydroxylase family. This enzyme was discovered by Nagatsu et al. in the laboratory
of Sidney Udenfriend at National Institute of Health in 1964 (63). TyrH hydroxylates
tyrosine forming L-3, 4-dihydroxyphenylalanine (DOPA); this is the rate-limiting step in
production of the catecholamines dopamine, norepinephrine and epinephrine.
TyrH is found in the central nervous system, adrenal gland, gut and retina. It forms
a homotetramer in solution with a mass close to 240 kD. It is predominantly found in the
cytoplasm (64). Rat TyrH has 498 residues forming three domains. There are four
different isoforms of human TryH, two in anthropoids and one in rat and cow (65). TyrH
is coded by a single gene in all species. Multiple isoforms are due to alternative splicing
of mRNA (66). All the sequence differences lie in the N-termini (67, 68). The C-
terminal region (156-498) of TyrH possesses the same catalytic activity as the whole
enzyme (69). The crystal structure of the C-terminal region of rat TyrH has been
determined (70).
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Structure and active site
The active site of TyrH is a 17 Å deep cleft at the center of the catalytic domain
basket. The entrance into the active site is guarded by two loops: residues 423−428 and
290−296, which are within 12 Å of each other across the top of the 30 Å long and 15 Å
wide active site. The N-terminus of the C-terminal region, located near this entrance in a
reasonable position for placement of the regulatory region, has been postulated to
function by directly controlling the accessibility of substrate or cofactor to the active site
(18, 32). The iron atom is 10 Å below the enzyme surface within the active site cleft; the
coordinating residues are His331, His336 and Glu376. These three residues are
conserved in all three aromatic amino acid hydroxylases. The iron atom is in a square
pyramidal geometry with His331 as the axial ligand and two water molecules joining the
iron ligands in the equatorial positions. The region opposite His331 is distinctly void of
density where a possible sixth ligand would be located (70). This iron coordination is
similar to that seen in the crystal structures of both the ferric and ferrous forms of an
iron-utilizing bacterial extradiol dioxygenase and is referred to as a 2-His-1-carboxylate
facial triad (71). Surrounding the iron binding site there are many conserved residues
that may play roles in catalysis. Phe300 and Phe309 are completely conserved in the 16
known mammalian gene sequences in this family. In the crystal structure of rTyrH, these
two residues are exposed on the surface of the active site and point toward the iron.
These residues may help to attract the hydrophobic portions of the substrate and cofactor
(70). Pro327 is another highly conserved residue. In the structure, Pro327 noticeably
protrudes into the active site. The proline Cβ and Cγ are 4.8 and 5 Å, respectively, from
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the active site iron atom. The mutant P327L TyrH shows reduced activity and a 20-fold
increased Km for BH4 (72). Another mutation, P327A, does not substantially affect the
Km value for the cofactor, but it does eliminate substrate inhibition. These data are
consistent with enzyme kinetic studies in which tyrosine is a competitive inhibitor versus
6MePH4 at concentrations above 150 μM (56).
The loop 131-150 in PheH takes on a dramatically different conformation in the
presence of amino acid, especially residue Tyr138, moving from an exposed position on
the surface to being buried in the active site (13). An alanine substitution scanning
mutagenesis study on the homologous polypeptide 177-191 in TyrH showed alterations
in the Km values for substrates, the Vmax value, and the coupling of BH4 oxidation to
tyrosine hydroxylation (73). TyrH mutants with alanine substituted for residues Lys183
to Pro186 had the greatest alteration on Ktyr values and Vmax values, consistent with the
central region of the loop being most critical for binding and catalysis. The homologous
residue of Tyr138 of PheH in TyrH is Phe184. Mutants of F184Y TyrH and of Y138F
PheH did show modest changes in the relative preferences of the two enzymes for
tyrosine versus phenylalanine, but the effects are better described as a loss of specificity
rather than a reverse of specificity. These results suggest that Phe184 of TyrH and
Tyr138 of PheH do not play dominant roles in determining amino acid substrate
specificity (73).
Several conserved residues in the active site have been studied by site-directed
mutagenesis. The charged residues Arg316, Glu326, Asp328 and Glu332 in the active
site of TyrH are conserved among all three hydroxylases. Mutagenesis has shown that
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Arg316 and Asp328 are important in tyrosine binding, presumably by interacting with
the carboxylate and amino moieties. Glu326 is not directly involved in catalysis. Glu332
is required for productive tetrahydropterin binding (74). Characterization of mutations of
the conserved residues Phe309 and Phe300 of TyrH showed that Phe309 plays an
indirect role in catalysis by maintaining the proper overall structure of the active site and
Phe300 plays a role in maintaining the strength of the interaction of the pterin with TyrH
(75). The conserved residue Asp425 of TyrH plays an important role in determining the
amino acid specificity. A possible reason is that carboxyl oxygen of Asp425 is necessary
to hydrogen bond to the hydroxyl group of tyrosine in order to properly orient that
substrate in the active site (62). Ser395 in the active site of rat TyrH is conserved in all
three members of the family of pterin-dependent hydroxylases. The hydroxyl oxygen of
Ser395 is located 2.78 Å from the imidazole N-1 of the iron ligand His331, an
appropriate distance for a hydrogen bond. A mutagenesis study suggests that Ser395 is
required for amino acid hydroxylation but not for cleavage of the oxygen−oxygen bond
(76).
Regulation
Inhibition by catecholamines
Catecholamines are competitive inhibitors versus the BH4, the first substrate to bind
in the TyrH kinetic mechanism (56, 77). A commonly accepted explanation of
inactivation of TyrH by binding with dopamine is that dopamine binds tightly to the
ferric iron atom to produce an inactive complex (78). TyrH has a single iron atom per
subunit that must be in the ferrous form for catalysis (79). The iron is readily oxidized to
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the ferric form during catalytic turnover resulting in inactive enzyme; the ferric iron can
be reduced by a tetrahydropterin (80). The oxidized enzyme can be trapped by the
product dihydroxyphenylalanine or DOPA.
Activation by phosphorylation
TyrH can be phosphorylated at Ser8, Ser19, Ser31 and Ser40 by different protein
kinases (81). Ser19 can be phosphorylated by CaM-PKII, and Ser31 can be
phosphorylated by the MAP kinases ERK1 and ERK2 (82). Ser8 is phosphorylated by a
novel proline-directed serine/threonine kinase (83). Among the four serines,
phosphorylation on Ser40 causes the most dramatic activation (66). Ser40 can be
phosphorylated by PKC, CaM-PKII, cGMP-dependent protein kinase, and cyclic AMP-
dependent protein kinase (PKA) (84, 85). CaM-PKII phosphorylates TyrH at Ser19
without any activation. However, this phosphorylated enzyme can be activated by
addition of 14-3-3 protein (86, 87). Unlike the strong activating effect of PKA
phosphorylation, phosphorylation by CaM-PKII and protein 14-3-3 can only moderately
increase activity at acidic pH.
The activation effects of phosphorylation on TyrH without any other ligands are
small (77, 82). The effects of most of these phosphorylations have not been established.
The effect of phosphorylation of Ser 40 is best understood. The primary effect of
phosphorylation at Ser40 is to decrease the enzyme's affinity for catecholamines (77, 78,
88). Phosphorylation of the ferric TyrH results in a 17-fold decrease in affinity for
DOPA and a 300-fold decrease in the affinity for dopamine (88). The reason for this
activation by phosphorylation is that TyrH requires ferrous iron atom for activity (79)
28
and phosphorylation of Ser40 releases catecholamines tightly bound to the ferric form
iron, allowing tetrahydrobiopterin to reduce the iron for activity.
Phosphorylation of TyrH and catecholamine binding result in opposite changes in
the structure of TyrH. TyrH phosphorylated at Ser40 has a shorter retention time on gel
filtration chromatography compared to TyrH alone, while dopamine-bound TyrH has a
slightly longer retention time (86). Binding of dopamine greatly decreases the sensitivity
of residues 33 and 50 in the regulatory domain to proteolysis, while phosphorylation of
Ser40 increases the sensitivity by a comparable amount (87). Truncated TyrH lacking
the first 39 residues is not inhibited by preincubation with dopamine (89). The
interaction between the regulatory domain and the amino moiety of the catecholamine is
critical to determine the affinity for a catecholamine (90). These results support a model
in which there is direct interaction between the regulatory domain and the amino group
of a catecholamine bound in the active site, preventing substrate access; phosphorylation
triggers a conformational change, weakening this interaction (90).
Allosteric regulation
Heparin, phospholipids, and polyanions have all been shown to increase the activity
of TyrH by interaction with the enzyme in a reversible manner (91-93). Polyanions bind
the regulatory domain of TyrH, specifically the N-terminal residues between 76 and 90
(69, 94). Therefore, affinity columns such as heparin-Sepharose (95) can be used to
purify TyrH. Nucleic acids are also reported to nonspecifically activate TyrH (96).
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Kinetic and chemical mechanism of TyrH
TyrH reacts through a fully sequential mechanism in which all the substrates bind
to the enzyme in the order of BH4 first, then oxygen, and finally tyrosine (56) . In
addition to the three substrates, TyrH also requires ferrous iron atom for its reaction(79).
TyrH is purified with ferric iron, and reaction requires pre-reduction of the metal atom.
BH4 or 6-methyltetrahydropterin (6MePH4) can rapidly reduce the iron atom (97). TyrH
can use tyrosine, phenylalanine or tryptophan as the amino acid substrate (62, 98). The
products of hydroxylation of phenylalanine by TyrH are mostly tyrosine and a small
amount of 3-hydroxyphenylalanine, with the Vmax value one fourth of that with tyrosine
and the Km value about 6-fold higher (95, 96). Tryptophan is a poor substrate for TyrH,
with a significantly lower Vmax value and higher Km value (56). Chimeric TyrH
containing the regulatory domain of PheH and catalytic domain of TyrH has similar
substrate specificity to TyrH, establishing that it is the catalytic domain that determines
substrate specificity (99).
 The chemical mechanism of TyrH is the most-studied among all three members of
aromatic amino acid hydroxylase family. In this mechanism, oxygen reacts with BH4 to
form a Fe(II)-μ-peroxypterin, a precursor of the hydroxylating intermediate. The peroxy
OO bond of this precursor is cleaved to form the actual hydroxylating intermediate,
Fe(IV)O, and 4a-hydroxypterin (Scheme 1.2) (76, 100, 101). In a recent study, this high
spin Fe(IV)O intermediate was directly detected by rapid-freeze quench Mössbauer
spectroscopy (102). The Fe(IV)O intermediate reacts with the aromatic side chain of the
tyrosine through an electrophilic aromatic substitution to form the product
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dihydroxyphenylalanine (DOPA) (103). The rate-limiting step in TyrH turnover is
release of DOPA and/or 4a-hydroxypterin (104).
Scheme 1.2. Chemical mechanism of TyrH.
Related diseases
The characteristics of TyrH deficiency include broad phenotypes ranging from
tyrosine-deficient DOPA-responsive dystonia to DOPA-unresponsive infantile
Parkinsonism and progressive infantile encephalopathy. Parkinson's disease (PD) is a
common neurodegenerative disorder with symptoms of tremor, bradykinesia and rigidity,
which has been associated with the degeneration of dopamine biosynthesis in the central
nervous system (105). A logical and efficient treatment for PD is to correct or bypass the
enzyme deficiency by treatment with L-DOPA, DA agonists, inhibitors of DA
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metabolism, or brain grafts with cells expressing TH (106). Surgical treatment and gene
therapy are novel treatments for PD, though extensive work still remains to be done
before clinical application. In addition, TyrH is also suspected to have a direct
pathogenetic role because the enzyme is a source of reactive oxygen species (ROS) in
vitro and a target for radical-mediated oxidative injury (107). However, this hypothesis
is difficult to test because it is hard to separate the possible pathogenetic effects from the
effects of catecholamines and other components of catecholaminergic neurons.
Tryptophan Hydroxylase
Overview of tryptophan hydroxylase
Tryptophan hydroxylase (TrpH) catalyzes the hydroxylation of tryptophan using
oxygen and BH4 as the other substrates. This enzyme produces 5-hydroxy-L-tryptophan
in the rate-limiting step of serotonin (5-hydroxytryptamine) synthesis. Serotonin is a
neurotransmitter that has been implicated in numerous physiological functions and
pathological disorders. Serotonergic dysfunctions are involved in psychiatric diseases
such as depression, anxiety, drug abuse, eating disorder and schizophrenia (108).
Serotonin is the precursor for melatonin. Melatonin regulates the behavioral and
physiological circadian rhythms, and may be involved in the sleep pathway (109). TrpH
has two isoforms (110). Isoform 1 (TPH1) is expressed mainly in the peripheral parts of
the body (111) and in the pineal gland (112). In the periphery, it is found in mast cells,
stem cells, and enterochromaffin cells in the pancreas, intestine and gastric system (113,
114). Isoform 2 (TPH2) is responsible for tryptophan hydroxylation in the brain (115).
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Overall structure
TrpH is a homotetramer with a mass of 51 kD for each subunit (116). As with PheH
and TyrH, TrpH is composed of three domains. Sequence alignments reveal 48%
sequence identity between rabbit TrpH and rat TyrH, and 53% identity between rabbit
TrpH and human PheH (117). The sequence identity of the catalytic domains of rabbit
TrpH and rat TyrH is 60%, whereas the identity of the regulatory domains is only 11%
(118).
A structure of doubly truncated (ΔNH102-ΔCOOH402) human TrpH has been
determined with 7, 8-dihydro-L-biopterin (BH2) bound and ferric iron (1MLW) (115).
The catalytic core of TrpH is a mixed α and β structure, similar to those of hPheH and
rTyrH, as well as C. violaceum PheH. The hTrpH active site consists of an
approximately 9 Å deep and 10 Å wide cavity. Lining the active site channel are two
loops, 263-269 and 363-372. This structure also shows that hTrpOH binds a catalytic
Fe(III) atom ~13 Å below the surface and at the intersection of the channel and the
opening to the active site. As in PheH, the iron in TrpH is octahedrally coordinated to
three residues, His272 (N-Fe distance of 2.1 Å), His277 (N-Fe distance of 2.0 Å), and
one carboxyl oxygen atom of Glu317 (O-Fe distance of 2.4 Å), together with three water
molecules: Wat1 (axial to His272, 2.2 Å to Fe), Wat2 (axial to His277, 2.3 Å to Fe), and
Wat3 (axial to Glu317, 2.2 Å to Fe. The oxidized cofactor BH2 π-stacks on Phe241 and
Tyr235, forming hydrogen bonds to Gly234 and Leu236. The pterin O4 atom is also
hydrogen bonded to two of the three water molecules coordinated to the iron, with
distances of 2.4 and 2.8 Å. Glu273 also forms two water-mediated hydrogen bonds to
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the pterin. The octahedral coordination of iron is approximately similar to what is seen in
the ferric doubly truncated hPheOH structure (5), in contrast to the five coordination
observed in ferric rTyrH (70).
The only crystal structure of TrpH with bound amino acid is for the catalytic
domain (Δ1-100/Δ415-445) of chicken TrpH isoform 1 (TrpH1) in complex with
tryptophan and an iron-bound imidazole (119). Tryptophan directly interacts with
residues Thr266, Ile367, Arg258, Ser337 and two water molecules. The tryptophan
stacks against Pro269 with a distance of 3.9 Å between the iron and the tryptophan,
yielding an angle of 141° between them. The iron binds His273, His278, and Glu318
(partially bidentate) and one imidazole in a distorted trigonal bipyramidal coordination.
As seen in PheH, binding of amino acid substrate triggers conformational changes.
Compared to the structure of the human TrpH1 without tryptophan, the structure of
chicken TrpH 1 is more compact, and the loops of residues Leu124-Asp139 and Ile367-
Thr369 close around the active site. Tyr126 corresponds to Tyr138 in PheH, and Phe184
in TyrH. Crystal structures of PheH have shown that this tyrosine changes from a
position on the surface to a buried position close to the active site upon binding of the
substrate analogue THA or NLE. In chicken cTrpH1, Tyr126 has not moved to a buried
position, but the loop has made an extra turn, still keeping Tyr126 on the surface where
it is packed against Phe137, with a triethylene glycol molecule nearby (4 Å). The
chicken TrpH1·Trp·imidazole structure is more like the PheH·BH4· thienylalanine
structure than the human TrpH1 structure (119).
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Regulation
TrpH is phosphorylated by CaM-PKII and PKA (120, 121). Ser58 is the
phosphorylation site for PKA (122). The phosphorylation site for CaM-PKII has not
been determined. However, Ser58 cannot be ruled out. Phosphorylation-dependent
activation of TrpH by both PKA and CaM-PKII requires the presence of an activator
protein that has been identified as a 14-3-3 protein (88, 89). Direct binding of 14-3-3 to
phosphorylated TrpH has been observed, with a Kd value of 30 nM (123). The binding of
14-3-3 is hypothesized to stabilize TrpH through an interaction with the regulatory
domain (123, 124). Another possible effect is that binding of 14-3-3 prevents
dephosphorylation of TrpH (123).
TrpH is subject to significant substrate inhibition when tryptophan is varied at a
fixed concentration of either BH4 or 6MePH4, and vice versa (123, 125). Unlike TyrH,
TrpH is not subject to feedback inhibition by its product 5-hydroxy-L-tryptophan (126).
L-DOPA has been reported to inhibit TrpH activity (127). Many Parkinson’s disease
patients undergoing L-DOPA treatment have the side effect of depression, which may be
explained by the reduced production of serotonin. Nitric oxide (NO) is another
compound found to modulate the TrpH activity. NO irreversibly inactivates TrpH (119,
125). The inactivation may occur through modification of sulfhydryls. TrpH is also
inhibited by thiol-binding compounds (N-ethylmaleimide and mercurials) (128) or other
agents that form disulfides in protein (DNTB and dithiodiglycolic acid) (122).
The substrate inhibition at high concentrations of tryptophan reported for TrpH
suggests an ordered kinetic mechanism (129). The binding order of amino acid and
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tetrahydropterin is likely random for TrpH (60). TrpH shares the same catalytic
mechanism as TyrH, forming an electrophilic Fe(IV)O hydroxylating intermediate (60).
The rate-limiting step in the reaction catalyzed by TrpH is oxygen addition to the
aromatic ring of the amino acid (130).
Substrate specificity
TrpH can also hydroxylate tyrosine and phenylalanine. Tyrosine is a very poor
substrate (125). Tyr236 is involved in BH2 binding and tryptophan binding. Two
positions of TrpH are believed to be involved in determining substrate specificity,
Phe314 (131, 132) and Ile367 (133). Trp372 is conserved in all TyrH sequences. The
residue at this position in TrpH is Phe314. Phe314 is conserved in all known tryptophan
hydroxylases. F314W TrpH no longer shows a preference for tryptophan over
phenylalanine as substrate, consistent with a role of this position in substrate specificity
(132). The residues corresponding to Ile367 are Val379 in PheH and Asp425 in TyrH.
Asp425 in TyrH is involved in determining the substrate specificity of TyrH.
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CHAPTER II
CHARACTERIZATION OF METAL LIGAND MUTANTS OF
PHENYLALANINE HYDROXYLASE: INSIGHTS INTO THE PLASTICITY OF A 2-
HISTIDINE-1-CARBOXYLATE TRIAD
Phenylalanine hydroxylase (PheH) is a tetrahydropterin-dependent nonheme
enzyme that catalyzes the hydroxylation of phenylalanine to tyrosine, an important
pathway for phenylalanine catabolism (Scheme 2.1) (81). As a liver enzyme, PheH is
critical for catabolizing excess phenylalanine in the diet. Consequently, a deficiency in
PheH results in the debilitating disease phenylketonuria (134). PheH belongs to the
small family of aromatic amino acid hydroxylases, all of which use tetrahydrobiopterin
as the source of electrons to hydroxylate the aromatic ring of an aromatic amino acid.
Tyrosine hydroxylase (TyrH) and tryptophan hydroxylase (TrpH) are the other two
members; these are the rate-limiting catalysts for catecholamine and serotonin
biosynthesis, respectively. The three eukaryotic enzymes form homotetramers in
solution (135-137). Each monomer consists of three domains: a regulatory domain at the
amino terminus, a catalytic domain and a tetramerization domain at the carboxyl
terminus (117, 129). The catalytic domains are homologous and contain all the residues
required for catalysis and the determination of substrate specificity (99), while the
regulatory domains show low levels of sequence identity, consistent with their diverse
regulatory mechanisms (129).
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Scheme 2.1. The phenylalanine hydroxylase reaction.
The similar structures of the catalytic domains (138) and a variety of mechanistic
studies suggest that the three aromatic amino acid hydroxylases share a common
catalytic mechanism (60). For all three enzymes, hydroxylation of the physiological
substrate occurs via an electrophilic aromatic substitution reaction with an activated
oxygen species (101, 103, 139). In the case of TyrH the latter has been shown to be an
Fe(IV) species (102), consistent with the proposed involvement of an Fe(IV)O as the
hydroxylating intermediate in all three enzymes (60). The reactivities of the
hydroxylating intermediates in all three enzymes are similar (140), and they have
overlapping substrate specificities (125, 140, 141), supporting the proposal for a
common Fe(IV)O intermediate. The iron atom in each is coordinated by two histidines
and a glutamate (70). This metal-binding arrangement has been named a “2-His-1-
carboxylate facial triad” and is also found in a variety of nonheme iron enzymes with
different three-dimensional structures, including the extradiol and Rieske dioxygenases,
the α-ketoglutarate-dependent hydroxylases, and isopenicillin N synthase (142). The
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ubiquity of the 2-His-1-carboxylate facial triad suggests that it is ideally suited for
formation of a high-valent iron-oxo hydroxylating intermediate (142).
The extent to which the 2-His-1-carboxylate facial triad is optimal for specific
reactions should in principle be reflected in the tolerance to substitution of the three
amino acid residues in the triad in the different families of enzymes containing this motif.
The metal sites of TyrH and PheH are shown in Figure 2.1. Mutagenesis of either
histidine in TyrH to alanine (143) or in PheH to serine (144) is reported to give inactive
enzyme. However, in the case of TyrH, less drastic mutations give more interesting
results (145). Both the H336E and H336Q enzymes retain significant activity at tyrosine
hydroxylation. H331E TyrH is unable to hydroxylate tyrosine, but is able to catalyze
tetrahydropterin oxidation in the absence of tyrosine. Finally, both E376Q and E376H
TyrH retain low activity for tyrosine hydroxylation. This very limited series of results
suggests that the different ligands in the 2-His-1-carboxylate triad differ in their
plasticity. As a test of this hypothesis for the aromatic amino acid hydroxylases in
general, the effects of mutating the iron ligands in PheH to histidine, glutamate or
glutamine have now been determined.
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Figure 2.1. Iron ligands in TyrH (green) and PheH (cyan). The structures are from PDB
files 1TOH and 2PHM.
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Materials and Experimental Procedures
Materials
Leupeptin and pepstatin A were from Peptides Institute, Inc. (Osaka, Japan).
Glycerol was from EM Science. Hepes was purchased from USB (Cleveland, Ohio).
Tetrahydrofuran, 2, 3-naphthalene dicarboxaldehyde and dihydropteridine reductase
(DHPR) were from Sigma. Restriction and DNA modification enzymes were purchased
from New England Biolabs (Ipswich, MA) and Promega (Madison, WI). Tween-80 and
6-methyltetrahydropterin (6MePH4) were from Calbiochem (San Diego, California).
Phenyl-Sepharose CL-4B was purchased from Amersham Biosciences (Sweden).
Catalase was from Roche Pharmaceuticals (Nutley, NJ).
Mutagenesis
The wild-type rat phenylalanine hydroxylase cDNA-containing plasmid pERPH5
was described previously (99). This plasmid was used as a template to construct
plasmids for expression of PheH mutants. Site-directed mutagenesis was carried out with
the Stratagene QuikChange Kit using pfu DNA polymerase. The mutagenic
oligonucleotides were from Integrated DNA Technologies, Inc. The sequences of the
oligonucleotides and the corresponding new restriction cleavage sites created are given
in Table 2.1. QIAfilter plasmid midi prep kits and QIAprep Spin miniprep kits were used
for purifying plasmids, which were used to transfect OmniMax competent cells from
Invitrogen (Carlsbad, California). Mutant plasmids were sent to the Gene Technology
Laboratory of Texas A&M University for DNA sequencing to confirm the mutations.
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Table 2.1. Oligonucleotides used to perform site-directed mutagenesis a
mutation Oligonucleotides sequence New digest
site
H285E 5’- gaa cct gac ATA tgg GAG ctc ttg gg – 3’ NdeI
H285Q 5’-cct gac ata tgc CAG gaa ctc ttg gga cat– 3’ NdeI
H290E 5’-gc cat gaa ctc ttg gga GAG GTA cct ttg ttt tca g– 3’ Acc651
H290Q 5’-gaa cct GAT atc  tgg cat gaa ctc ttc gga CAG gtg cct– 3’ EcoRV
E330H 5’-c tgg ttt act gtg CAC ttt ggg ctt tgc– 3’ ApalI
E330Q 5’-tgg ttt act gtg CAG ttt GGT CTC tgc aag gaa gga– 3’ BsaI
a
 The changes from the wild-type sequence are capitalized.
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Bacterial cell growth and protein purification
Mutant and wild-type PheH were expressed in C41(DE3) E. coli and purified on a
Phenyl-Sepharose CL-4B column according to the protocol of Daubner et al. (99),
except for the use of 50 mM Hepes and 15% glycerol instead of 50 mM Tris–HCl and
10% glycerol in the elution buffer. In addition, 50 μM EDTA was added to the elution
buffer. Cells expressing wild-type PheH were grown at 37 °C, while cells expressing the
mutant enzymes were grown at 22 °C after induction. The purified proteins were
concentrated and stored in 50 mM Hepes, 15% glycerol, 1 μM leupeptin and 1 μM
pepstatin A, pH 7.0, at −80 °C.
Assays
For wild-type PheH, the formation of tyrosine from phenylalanine was determined
by monitoring the absorbance increase at 275 nm (146). For the mutant enzymes, a more
sensitive HPLC assay (147, 148) was used. The standard conditions were 5 mM
dithiothreitol, 50 mM Hepes, pH 7.0, at 25 °C, and varied amounts of ferrous
ammonium sulfate, phenylalanine and 6MePH4 as indicated in figure and table legends.
The total volume of each assay was 100 μl. The assays were quenched after 1 min and
derivatized with 2, 3-naphthalene dicarboxaldehyde before being injected onto a
2.1 × 150 mm Waters Nova-Pak C18 column with fluorescence detection.
A coupled assay with dihydropteridine reductase and NADH was used to measure
tetrahydropterin oxidation (99). The standard condition was 30 mM Hepes, pH 7.0,
250 μM NADH, 200 μM 6MePH4, 4 mM phenylalanine, 0.2 mM ferrous ammonium
sulfate, 0.1 mg/ml catalase, and 0.1 U/ml dihydropteridine reductase at 25 °C. The total
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volume was 1 ml. The amount of 6MePH4 oxidation was determined by monitoring the
decrease of absorbance at 340 nm and correcting for autoxidation of 6MePH4. In order to
determine the ratio of phenylalanine hydroxylation to 6MePH4 oxidation, a 100 μl
aliquot was removed from the cuvette after 1 min and quenched with 100 μl 10 mM
NaCN, pH 9, 100 μl 10 mM 2, 3-naphthalene dicarboxaldehyde in methanol, and
0.34 ml 10 mM sodium borate buffer, pH 9, and then analyzed by HPLC to measure
tyrosine. Steady-state kinetic data were fit to the Michaelis–Menten equation using the
program KaleidaGraph (Synergy Software, PA).
Results
Expression and purification of PheH mutant proteins
The three iron ligands of PheH, His285, His290 and Glu330, were each replaced
with glutamate, histidine or glutamine using site-directed mutagenesis. All the mutant
enzymes were expressed at significantly higher levels in C41(DE3) E. coli than in
BL21(DE3). A significant amount of protein was found in insoluble inclusion bodies for
all of the mutant proteins; this could be minimized by growth at 22 °C. The yield of the
mutant enzymes was about 1 mg of purified protein per liter of bacterial culture,
significantly less than the typical 20 mg/l of the wild-type enzyme.
Kinetic characterization of PheH mutant proteins
The activities of all of the mutant proteins were significantly less than that of the
wild-type enzyme. Still, by using a sensitive HPLC-based assay it was possible to
determine the kinetic parameters of most of the mutant proteins. While PheH requires
Fe(II) for activity, the affinity of the wild-type enzyme for iron is high enough that the
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enzyme is fully active even in the absence of added iron. However, the activities of all
the mutant proteins are clearly iron-dependent (Figure 2.2). Mutation of Glu330 has the
greatest effect on the value of KFe, the concentration of ferrous ion required for half-
maximal activity, while the magnitude of the effects of mutating the two histidines differ
with the individual mutation (Table 2.2). Even in the presence of saturating
concentrations of Fe(II), the apparent Vmax values for the H285E and E330Q enzymes
decrease by 105-fold from the wild-type value. Because of these very low activities,
further kinetic characterization of these two enzymes was not attempted. The Km values
for phenylalanine and 6MePH4 for the remaining mutant enzymes are given in Table 2.2.
Mutation of any of the iron ligands increases the K6MePH4 value about one order of
magnitude. The Kphe values of mutants similarly increase 3- to16-fold. The Kphe value of
H285Q PheH is the largest at about 15-fold the wild-type value. H290E and E330H
PheH display more modest increases.
Hydroxylation stoichiometry of PheH mutant proteins
The activity of PheH can be determined by following the formation of tyrosine or
of dihydropterin. For the wild-type enzyme these yield the same result, since
phenylalanine hydroxylation is tightly coupled to tetrahydropterin oxidation. This need
not be the case for mutant proteins, where unproductive breakdown of an iron–oxygen
intermediate to release hydrogen peroxide can occur without hydroxylation of the amino
acid. The relative stoichiometries of tyrosine formation and 6MePH4 oxidation for each
of the enzymes were determined using a coupled assay with NADH-dependent
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Figure 2.2. Iron dependence of tyrosine formation by PheH mutant enzymes. (A) E330H (open triangles), E330Q (filled
triangles), and H285E (filled squares); (B) H290Q (open circles), H285Q (open squares), and H290E (filled circles).
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Table 2.2. Steady-state kinetic parameters for phenylalanine hydroxylation by PheH mutant enzymes*
kinetic parameter wt PheHa H285Eb H285Qc H290Ed H290Qb E330Hb E330Qb
Vmax (min-1) 399±14 0.035±0.003 2.0±0.15 1.3±0.4 4.3±0.1 0.35±0.07 0.035±0.009
KFe (mM) NA 0.16±0.06 0.60±0.11 3.00±1.4 0.03±0.01 3.9±1.5 3.2±1.9
K6MePH4 (mM) 0.05±0.01 NDe 0.82±0.40 0.23±0.04 0.38±0.11 0.25±0.074 ND
Kphe (mM) 0.43±0.04 ND 6.9±3.1 3.4±2.1 1.2±0.4 1.6±0.4 ND
* Commonly used conditions: 5 mM dithiothreitol, 50 mM Hepes, pH 7, at 25°C.
a
 0.2 mM ferrous ammonium sulfate, 2 mM phenylalanine, 0.2 mM 6MePH4.
b
 4 mM ferrous ammonium sulfate, 5 mM L-phenylalanine, 2 mM 6MePH4.
c
 2 mM ferrous ammonium sulfate, 12 mM L-phenylalanine, 2 mM 6MePH4.
d
 6 mM ferrous ammonium sulfate, 8 mM L-phenylalanine, 2 mM 6MePH4.
e
 ND, not determined.
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dihydropteridine reductase to measure 6MePH4 oxidation and an HPLC assay to
determine the amount of tyrosine formed in the same reaction mixture. All of the
enzymes oxidized an excess of 6MePH4 relative to the amount of tyrosine formed (Table
2.3). The His285 mutant enzymes exhibited the greatest uncoupling of 6MePH4
oxidation and phenylalanine hydroxylation, while the two partial reactions were most
tightly coupled with the His290 mutant enzymes. Knowledge of these stoichiometries
made it possible to calculate the Vmax value for 6MePH4 oxidation by each of the mutant
enzymes by dividing the Vmax value for tyrosine formation by the stoichiometry (Table
2.3). Based on the ability to catalyze 6MePH4 oxidation, the H285Q enzyme is only 5-
fold less active than the wild-type enzyme, while the H285E enzyme is another 100-fold
less active. In contrast, the 6MePH4 oxidation activities of the other four mutant
enzymes are comparable at two orders of magnitude less than the wild-type value.
Discussion
The conservative mutations of the iron ligands in PheH described here affect
virtually all aspects of catalysis. Mutagenesis of the metal ligands appears to have effects
on protein stability in addition to the effects on catalysis. All of the mutant proteins
described here readily form inclusion bodies when expressed at 37 °C, in contrast to the
wild-type enzyme, and yield lower amounts of active protein even when grown at lower
temperatures. Moreover, attempts to obtain enzymes containing multiple mutations were
not successful (results not shown). The lower yields of the mutant proteins are probably
not due to the loss of a stabilizing effect of bound iron, since wild-type versions of the
aromatic amino acid hydroxylases can readily be isolated in large amounts even when
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Table 2.3. Coupling of phenylalanine hydroxylation to 6MePH4
oxidation for the wild-type and mutant PheH enzymes*
Enzyme Phenylalanine
hydroxylation /6MePH4
oxidation a
6MePH4 oxidation
     Vmax (min -1) b
Wild-type PheH 0.99 ± 0.05 403 ± 24
H285E 0.062 ± 0.009 0.68 ± 0.11
H285Q 0.031 ± 0.008 67 ± 16
H290E 0.15 ± 0.03 8.7 ± 2.6
H290Q 0.42 ± 0.06 10 ± 1.4
E330H 0.12 ± 0.03 1.8 ± 0.48
E330Q 0.079 ± 0.017 0.44 ± 0.15
* 30 mM Hepes (pH 7.0), 250 µM NADH, 200 µM 6MePH4, 4 mM
L-phenylalanine, 0.2 mM ferrous ammonium sulfate, 0.1 mg/ml
catalase, 0.1 unit/ml dihydropteridine reductase.
a
 Determined from the amount of 6MePH4 oxidation in 1 min as
measured using an NADH-linked assay and the amount of tyrosine
produced in the same sample in 1 min as measured by HPLC.
b
 Calculated from the value for phenylalanine hydroxylation /
6MePH4 oxidation and the Vmax for phenylalanine hydroxylation.
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containing substoichiometric iron or in the apo form (69, 125, 149, 150). Instead it
suggests that interactions of the side chains of the metal ligands with other residues in
the protein are important for structural integrity. A corollary of this is that other residues
in the protein play a significant role in properly positioning the metal ligands for metal
binding and reactivity.
Still, the results do allow some general distinctions to be drawn about the plasticity
of the individual residues, especially when combined with the results of similar
mutations in TyrH (145). The results also show that there are significant differences in
the plasticity of these residues in the two enzymes. In combination, the two mutations of
Glu330 in PheH have the greatest effects on the Vmax value for 6MePH4 oxidation and
tyrosine hydroxylation and intermediate effects on the coupling of these two partial
reactions. These two mutations also have the greatest effects on iron affinity as measured
by the dependence of activity on the iron concentration. A qualitatively similar result
was obtained with TyrH, in that the Glu376 mutant enzymes were on average the least
active. Both structural (11) and spectroscopic (151) studies of the iron site in PheH show
that Glu330 is a monodentate ligand to the metal in the resting enzyme, but binds in
bidentate fashion once both amino acid and tetrahydropterin are bound. However, the
structure of TyrH with an amino acid bound has not been determined, so there is no
direct evidence to date that the glutamate in that enzyme must be able to bind the iron
with both carboxylate oxygens. The present results with PheH are consistent with the
need for a negative charge at this position for iron binding and for the ability to act as a
bidentate ligand for efficient formation of the Fe(IV)O intermediate and its reaction with
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the amino acid substrate in that enzyme. The similarities in the effects of mutating this
residue in TyrH and PheH support a similar requirement for bidentate binding in TyrH.
Mutations of His290 yield the highest Vmax values for tyrosine formation, with
mutation to glutamate resulting in greater uncoupling of the two reactions. A similar
result was found for TyrH, in that the H336Q enzyme was the most active mutant
protein of those examined, although the activity in that case was much higher at one-
third the activity of the wild-type enzyme. In general, mutation of His290 in PheH to
glutamate has a much more deleterious effect than mutation to glutamine. The KFe value
for the H290E enzyme is two orders of magnitude greater than that of H290Q PheH.
This likely reflects the need for conservation of charge for iron binding. The greater
effect of the H290E mutation on the Km value for phenylalanine also likely reflects the
detrimental introduction of a negative charge into the hydrophobic active site. In contrast,
the coupling of 6MePH4 oxidation and phenylalanine hydroxylation is disrupted the least
in these two mutant proteins, although substitution with glutamate again is more
detrimental. This is consistent with proper positioning of the amino acid in the active site
once it binds, despite the lower affinity.
The two mutations of His285 also have disparate effects. His285 plays two roles in
the active site of PheH. In addition to being a metal ligand, the imidazole ring of His285
stacks on the side chain of the amino acid substrate. When the homologous residue in
TyrH, His331, is mutated to glutamate, binding of the amino acid substrate is eliminated
and the enzyme becomes a tetrahydropterin oxidase (145). In that case it was not
possible to characterize the effect of a mutation to glutamine. With PheH, the activity of
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the H285E enzyme at tyrosine formation is too low to measure a Kphe value, but the
tetrahydropterin oxidation activity does require the amino acid substrate. Thus, the
dramatic loss of the need for binding of an amino acid substrate to activate the iron for
reaction with oxygen is not seen when this residue is mutated in PheH. H285Q PheH
enzyme has the highest Kphe value of the four mutant proteins with enough activity to
measure this value, consistent with disrupted phenylalanine binding. Both of these
mutant proteins exhibit very low coupling of 6MePH4 oxidation to tyrosine formation,
again consistent with altered positioning of the amino acid substrate in the active site.
The H285Q enzyme is quite active as a phenylalanine-dependent tetrahydropterin
oxidase, while the H285E enzyme has activity comparable to that of the two His290
mutant proteins. Overall, mutation of either histidine residue is less disruptive of
tetrahydropterin oxidation than is mutation of the glutamate, consistent with the critical
importance of the change to bidentate binding of this residue for subsequent reactions.
The plasticity in the metal ligands in PheH is much less than is the case for TyrH
(145). In both enzymes, mutagenesis of the glutamate residue is generally more
disruptive of catalysis than is mutation of either histidine. Replacement of either
histidine with glutamate is more disruptive than replacement with glutamine, consistent
with the more conservative nature of the latter change. Of the two histidines, His290 of
PheH is less sensitive to mutagenesis than is His285; a similar situation was found for
the homologous residue in TyrH. However, mutating His285 in PheH does not have the
same effect on the need for an amino acid substrate that mutation of the analogous
mutation has in TyrH, establishing this effect as specific to TyrH instead of a reflection
52
of the general plasticity of the iron ligands in this enzyme family. The iron ligands of
TyrH and PheH are virtually superimposable on one another (Figure 2.1) and the two
enzyme share overlapping substrate specificities (62, 99). Indeed, mutating Asp425 in
TyrH to valine converts it to an enzyme which is a better catalyst for converting
phenylalanine to tyrosine than is wild-type PheH (62). Asp425 does not interact directly
with either substrate or with the iron in TyrH, so that the ability to convert the enzyme to
PheH establishes that there is no difference in the reactivities of the iron site in the two
enzymes. PheH has a much more restricted substrate range than does TyrH (74, 99) and
binds iron more tightly. These properties may reflect an active site that is optimized for
iron binding and amino acid hydroxylation to a greater extent in PheH than in TyrH and
that is consequently less tolerant of any disruption.
The α-ketoglutarate-dependent family of nonheme monooxygenases also contains a
2-His-1-carboxylate metal site, although the acidic residue is aspartate. The effects of
mutating the metal ligands in a number of these enzymes have been determined, as
summarized in Grzyska et al. (152). In many cases residual activities of <1% were not
measurable, limiting the conclusions one can draw. However, even with this caveat there
are discernable differences in the sensitivities to substitution of the three metal ligands in
this enzyme family. Using the numbering of TauD, mutation of His99 to other residues
generally yields enzyme with no detectable activity. In TauD the H99E and H99Q
enzymes have Vmax values of about 0.5% the wild-type enzyme. His99 is coplanar with
the α-ketoglutarate substrate in the active site, so that mutation of this residue would also
be expected to disrupt substrate binding analogously to the effects of mutating His285 in
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PheH. In contrast, mutation of His255 in TauD and related enzymes yields enzyme with
significant activity in a number of cases. For example, H255Q and H255E TauD have
Vmax values that are 89 and 36% the wild-type values. Finally, mutation of the aspartate
residue to anything but glutamate generally yields enzyme with no reported activity.
Thus, the general pattern for the α-ketoglutarate-dependent family of hydroxylases is
similar to that with the pterin-dependent enzymes. The acidic residue in the 2-His-1-
carboxylate facial triad is very sensitive to mutagenesis. Of the two histidine residues,
the residue interacting directly with a substrate, either α-ketoglutarate or the aromatic
amino acid, is also not tolerant to replacement with other amino acids, while the other,
His285 here and His255 in TauD, is quite plastic, tolerating replacement with glutamine
or glutamate.
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CHAPTER III
REGULATION OF PHENYLALANINE HYDROXYLASE:
CONFORMATIONAL CHANGES DETECTED BY H/D EXCHANGE AND MASS
SPECTROMETRY
Phenylalanine hydroxylase (PheH) is a mononuclear non-heme iron containing
monooxygenase (129). This enzyme is a liver enzyme catalyzing the hydroxylation of
phenylalanine to form tyrosine using molecular oxygen and tetrahydrobiopterin (BH4),
the rate limiting step in the catabolic degradation of phenylalanine (60), (134). A
deficiency or defect in PheH causes the genetic disease phenylketonuria (PKU), a
common metabolic disorder resulting in mental retardation (153). PheH belongs to the
aromatic amino acid hydroxylase family that has two other members, tyrosine
hydroxylase (TyrH) and tryptophan hydroxylase (TrpH). TyrH and TrpH hydroxylate
tyrosine and tryptophan forming the neurotransmitters L-DOPA and serotonin,
respectively (81). The three enzymes have similar chemical mechanisms, forming
Fe(IV)O intermediate to hydroxylate an amino acid. Each enzyme is a homotetramer
with subunits consisting of three domains, a regulatory domain, a catalytic domain and a
tetramerization domain, proceeding from the N-terminus to the C-terminus. The iron
atom lies at the center of the hydrophobic active site in the catalytic domain. The three
enzymes have high identity in the catalytic domains and low identity in the regulatory
domains (99, 117).
PheH is strictly regulated to control the metabolism of phenylalanine. Activation by
phenylalanine, inhibition by BH4 and phosphorylation of Ser16 are the three main
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mechanisms of regulation (81). Preincubation of PheH with phenylalanine can increase
the activity by more than 100-fold (19). Several studies have suggested that the
activation of PheH by phenylalanine is accompanied by conformational changes in the
protein. For example, PheH can absorb to Phenyl-Sepharose only when phenylalanine is
present. Phenylalanine treatment is proposed to induce a conformational change that
exposes hydrophobic residues that interact with the resin (22). Treatment of PheH with
phenylalanine also results in increased fluorescence emission, suggesting a
conformational change that exposes buried tryptophan(s) (154). Pretreatment with
phenylalanine and BH4 have opposite effects on the susceptibility of PheH to limited
proteolysis by chymotrypsin (155). Surface plasmon resonance has also provided
evidence for a slow reversible conformational transition upon binding phenylalanine
(156). There is a lag in the initial rate of tyrosine formation if assays are started by
adding enzyme; preincubation of PheH with phenylalanine eliminates the lag while
preincubation with BH4 increases it (19). Based on the opposite effects of phenylalanine
and pterin, Shiman proposed a model in which PheH is purified as an inactive form.
Treatment with phenylalanine induces a conformational change and converts the enzyme
into the active form while treatment with BH4 traps the enzyme in a BH4-PheH complex
that is harder to activate (39, 40, 149).
The only available structures of PheH with an amino acid substrate are ternary
complexes consisting of the catalytic domain of human PheH with Fe(II), BH4, plus 3-
(2-thienyl)-L-alanine or L-norleucine (6). The ternary complex has a slightly more
compact structure compared to the binary complex of hPheH-Fe(II)∙BH4. Two regions
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display the largest differences when an amino acid is bound: the surface loop containing
residues 131-155, in which Tyr138 is 9.6 Å closer to the iron atom, and the iron ligand
residue Glu330, which binds iron in bidentate fashion in the ferrous complex. However,
these structures provide no insight into the changes in the regulatory domain associated
with phenylalanine or BH4 binding. Indeed, the isolated catalytic domain does not
require activation by phenylalanine (150). The only crystal structure containing the
regulatory domain is a dimeric rat PheH lacking the C-terminal 24 residues of the
tetramerization domain (8). This structure shows N-terminal residues 19-33 extending
over the active site pocket. Based on this structure, Jennings et al. (23) proposed that the
residues 19-33 (also called N-terminal autoregulatory sequence) obstruct the entry of the
active site in the absence of phenylalanine and binding of phenylalanine activates the
enzyme by displacing the sequence. NMR studies support this model, in that a number
of sharp resonances attributed to the N-terminal autoregulatory sequence become weaker
in the presence of phenylalanine (157).
Phosphorylation by PKA also activates PheH (32). The phosphorylation site is
Ser16 (24). Phosphorylated PheH can be further activated by treatment with
phenylalanine but lower concentrations are required for full activation (158, 159).
Molecular dynamics simulations suggest that the conformational change induced by
phosphorylation is localized to the regions around Ser16 (160, 161). This result is
consistent with the finding that the structures of unphosphorylated and phosphorylated
enzymes have no significant difference, since the first N-terminal 18 residues are not in
the structures. Based on these data, Kobe et al. (157) proposed that phosphorylation of
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PheH only causes a local change in the structure that alters the electrostatic interaction of
the N-terminal autoregulatory sequence with the active site.
Hydrogen/deuterium exchange mass spectrometry (HXMS) has been proven to be a
powerful tool to study the structure and dynamics of proteins in solution (162, 163). We
have used HXMS to probe the structural changes accompanying activation by
phenylalanine binding and phosphorylation and inhibition by BH4 binding and reveal the
local dynamic motions and connections between regulation and structure in PheH.
Materials and Experimental Procedures
Materials
ATP and phosphatase inhibitor cocktail 1 were purchased from Sigma-Aldrich
Chemical Co. (Milwaukee, WI). Phenyl-Sepharose CL-4B was purchased from
Amersham Biosciences (Sweden). Porcine stomach pepsin A was from Worthington
Biochemical Co. (Lakewood, NJ). Deuterium oxide (D2O, 99% D) was from Cambridge
Isotope Laboratories (Andover, MA). Pepstatin A and leupeptin were from Peptides
Institute, Inc (Osaka, Japan). The γ-32P ATP (10 μCi/μl) was purchased from Perkin
Elmer Life and Analytical Science (Boston, MA).
Protein purification and preparation
The purification of wild-type rat PheH and the catalytic domain (∆117PheH) were
described previously (150, 164). To prepare PheH containing ferrous iron, 45 ml
concentrated wild-type PheH (about 2 mg/ml) in 50 mM Hepes, pH 7.0, 15% glycerol, 1
μM pepstatin A and 1 μM leupeptin was dialyzed overnight against 1 liter of the same
buffer plus 50 mM EDTA and 50 mM nitrilotriacetic acid (NTA), pH 7.0, with one
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buffer change. The dialysis buffer was then changed to 1 liter of the same buffer without
EDTA and NTA with three changes over 12 h. After centrifuging the sample at
33,800×g for 20 min, the supernatant was stored at -80 °C. The iron content of PheH
was determined as 90% apoenzyme by atomic absorption spectroscopy (80). To
determine the amount of phenylalanine bound to PheH, an aliquot of enzyme was
denatured by heating at 100 °C for 30 min, and injected onto a reverse-phase HPLC
using the method as described previously (165). The ratio of phenylalanine to PheH was
about 10%. The PheH activity was determined using a coupled assay with
dihydropteridine reductase, measuring the decrease in absorbance at 340 nm upon
NADH oxidation (166).
The PKA catalytic domain was purified from bovine heart as described by
Flockhart and Corbin (167). Preliminary experiments used γ-32P ATP to monitor the
extent of phosphorylation as described before (168). The conditions for preparation of
phosphorylated enzyme for mass spectrometry were 0.3 mM unlabeled ATP, 10 mM
MgCl2, 0.8 μM PKA, 12 μM PheH, and 50 mM Hepes, pH 7.0, at room temperature
(about 22 °C) for 1 h. After the first 15 min, additional PKA and ATP were added for a
final concentration of 1 μM PKA and 0.4 mM ATP. The total reaction volume of 65 ml
contained about 40 mg PheH. The phosphorylated PheH was isolated by FPLC using a
HiPrep 16/10 Q XL Column (GE Healthcare Life Science) in 50 mM Hepes, 5%
glycerol, pH 7.0, with a gradient of 0-0.3 M KCl. The phosphorylated PheH solution (
60 ml) was then dialyzed against 1 liter of 50 mM Hepes, 15% glycerol, 50 μM EDTA,
60 μl phosphatase inhibitor cocktail 1, 1 μM pepstatin A and 1 μM leupeptin at 4 °C.
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The phosphorylated PheH was then concentrated to about 200 μM using an Amicon
Ultracel-30k (Millipore) ultra centrifugal filter and stored at -80 °C.
H/D exchange
The H/D exchange reactions were initiated by diluting 15 μl freshly thawed PheH
(about 150 μg) into 300 μl of 50 mM Hepes, pD 7.0, in D2O containing phenylalanine or
BH4 or no addition, at 25 °C. Before dilution, 2 μl of ferrous ammonium sulfate in 1 mM
HCl was added to enzyme to achieve a subunit to iron ratio of 1:1 (mole/mole). To
prevent ferrous iron oxidation, all the solutions were prepared anaerobically by applying
cycles of vacuum and argon. During H/D exchange, the tube containing the enzyme in
D2O solution was sealed and filled with argon. The concentrations of phenylalanine and
BH4 were 5 mM and 400 μM, respectively. Twenty μl samples were taken out with an
air-tight syringe at different time points and quenched with 20 μl ice-cold 100 mM
sodium citrate buffer, pH 2.4. The mixture was immediately frozen in liquid nitrogen
and stored at -80 °C.
For mass spectrometry, the 40 μl mixture was rapidly thawed, and 2 μl pepsin was
added. The ratio of pepsin to PheH was about 1:1 by weight. After 5 min on ice, 20 μl of
sample was injected onto a Vydac C18 HPLC column (2.1 mm × 150 mm). The HPLC
buffers, column, injection loop and tubing were all immersed in an ice bath to minimize
back-exchange. After desalting with 98% solvent A (0.1% formic acid in H2O, pH 2.4)
for 3 min, a 15 min linear gradient of 20-50% solvent B (0.1% formic acid in acetonitrile,
pH 2.4) was used to separate the peptides. The flow rate was 200 μl / min. The outlet of
the HPLC was connected to a Thermo Finnigan LCQ DECA XP ion-trap mass
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spectrometer. All the peptides analyzed eluted after 6 to 12 min and with m/z values of
400 to 2000. The analysis for each condition was performed at least twice. Tandem mass
spectrometry (MS/MS) under the same conditions using water instead of D2O was used
for peptide identification. The software used to process MS/MS data was
TurboSEQUEST from Thermo Finnigan, version 3.1. Singly, doubly and triply charged
peptides were analyzed. The mass spectrometry experiments were all conducted in the
Protein Chemistry Laboratory at Texas A&M University.
To determine the back-exchange rate, 15 μl of 200 μM PheH plus 2 μl of ferrous
ammonium sulfate in 1 mM HCl was diluted with 300 μl of 50 mM Hepes, pH 7.0 in
H2O followed by mixing with 315 μl of 100 mM sodium citrate buffer (pH 2.4). Pepsin
was then added to give a ratio of pepsin to PheH of 1 by weight. After pepsin digestion
on ice for 5 min, the mixture was immediately frozen with liquid nitrogen and
lyophilized. The lyophilized powder was dissolved in 315 μl of 50 mM Hepes D2O (pD
7.5) and heated for 30 min at 100 °C. The solution was then incubated at 25 °C for 6 hrs.
For mass spectrometry, 20 μl of the solution was mixed with 20 μl of 100 mM sodium
citrate buffer (pH 2.4). After 5 min on ice, 20 μl of the sample was injected onto the
HPLC. The back-exchange of individual peptides was 30-35%.
Data processing
The MS data exported using Thermo Finnigan Xcalibur software were transferred
into HX-Express, a Microsoft Excel-based software for generating a deuterium
incorporation curve (169). The percent H/D exchange was calculated directly without
correction for back-exchange. All of the data in figures are averages of at least two
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separate runs. The kinetics of exchange were fit to equation 1 or equation 2 using
KaleidaGraph (version 4.0), where N is the total percent of exchange over the observed
time and A and B are the percent of amide hydrogens exchanging with rate constants k1
and k2, respectively.
Y = N - Ae-k1t           (1)
Y = N - Ae-k1t - Be-k2t     (2)
Results
Phosphorylation of PheH
Preliminary experiments were conducted to establish the conditions for
stoichiometric phosphorylation of PheH by PKA. Figure 3.1 shows the progress curve
for the reactions under the conditions described in Experiment Procedures. After 30 min,
the ratio of incorporated 32P to PheH reached over 95%. The reaction was scaled up
using unlabeled ATP together with 40 mg PheH under the same conditions. The
phosphorylated PheH was purified using a Q-Sepharose column. To rule out the
possibility that the phosphorylation reaction was not complete, a phosphorylation
reaction was performed with the phosphorylated PheH protein after the Q-Sepharose
column. No radioactivity incorporation was observed.
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Figure 3.1. Progress curve for phosphorylation of PheH by PKA. The conditions are 0.3
mM [γ-32P]-ATP, 10 mM MgCl2, 0.8 μM PKA, 12 μM PheH, and 50 mM Hepes, pH 7.0,
at room temperature for 1 h. After the first 15 min, additional PKA and ATP were added
for a final concentration of 1 μM PKA and 0.4 mM ATP. The curve is from a single
exponential fit of the data.
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Peptide identification and sequence coverage
Before conducting the H/D exchange, the identities of peptides generated by pepsin
digestion of wild-type PheH, the catalytic and tetramerization domains of PheH
(∆117PheH), and phosphorylated PheH were determined by tandem mass spectrometry
(MS/MS). For wild-type PheH, a total of 30 peptides could be routinely identified,
covering 80% of the protein sequence (Figure 3.2). For ∆117PheH, a total of 31 peptides
of could be identified covering 91% of the protein sequence. A total of 28 peptides of
phosphorylated PheH were identified covering 79% of the protein sequence. The back-
exchange ratio in this study was determined as about 40%.
H/D exchange of wild-type PheH
To monitor the conformational change of wild-type PheH upon phenylalanine
binding, 150 μg wild-type PheH was diluted with 20 volumes of 5 mM phenylalanine,
50 mM Hepes, pD 7.0, in D2O to start the H/D exchange at 25 °C. Aliquots of 20 μl
were taken at different time points from 30 s to 4 h and immediately quenched by
mixing with 20 μl of ice-cold 100 mM sodium citrate buffer, pH 2.4. The 40 μl mixture
was digested with pepsin (equal weight to PheH) for 5 min on ice, followed by injection
onto an HPLC with a Vydac C18 HPLC column. The deuterium incorporation into wild-
type PheH in the presence of phenylalanine was compared with that in the absence of
phenylalanine. Most regions have similar exchange patterns under these two conditions
(Figure 3.3). Eight peptides exhibit significantly different exchange patterns with an
increased level of deuterium incorporation in the presence of phenylalanine (Figure 3.4).
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MAAVVLENGVLSRKLSDFGQETSYIEDNSNQNGAISLIFSLKEEVGALAKV
LRLFEENDINLTHIESRPSRLNKDEYEFFTYLDKRTKPVLGSIIKSLRNDI
GATVHELSRDKEKNTVPWFPRTIQELDRFANQILSYGAELDADHPGFKDPV
YRARRKQFADIAYNYRHGQPIPRVEYTEEEKQTWGTVFRTLKALYKTHACY
EHNHIFPLLEKYCGFREDNIPQLEDVSQFLQTCTGFRLRPVAGLLSSRDFL
GGLAFRVFHCTQYIRHGSKPMYTPEPDICHELLGHVPLFSDRSFAQFSQEI
GLASLGAPDEYIEKLATIYWFTVEFGLCKEGDSIKAYGAGLLSSFGELQYC
LSDKPKLLPLELEKTACQEYSVTEFQPLYYVAESFSDAKEKVRYTFAATIP
RPFSVRYDPYTQRVEVLDNTQQLKILADSINSEVGILCNALQKIKS
Figure 3.2. Sequence coverage of PheH. The peptides analyzed in this study are
indicated by double-headed arrows. The black, green and magenta colors represent
unphosphorylated PheH, phosphorylated PheH and ∆117PheH, respectively. The
regulatory and tetramerization domains are in blue and brown, respectively. The
catalytic domain is in black.
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Figure 3.3. Deuterium incorporation into peptides of wild-type PheH in the absence (○, dashed line) and presence (●, solid line) of
phenylalanine. Percent deuterium incorporation was calculated by dividing the observed deuterium incorporation by the number
of exchangeable peptides bonds in a peptide. There is no adjustment for back-exchange. The curves were fit by equation 1, except
the data for peptide 164-174 in the presence of phenylalanine were fit by equation 2.
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Figure 3.4. Peptides of wild-type PheH showing large differences in deuterium
incorporation in the absence (○) and presence (●) of phenylalanine. Percent deuterium
incorporation was calculated by dividing the observed deuterium incorporation by the
number of exchangeable peptide bonds in a peptide. There is no adjustment for back-
exchange. The curves were fit by equation 1, except the data for peptide 164-174 in the
presence of phenylalanine were fit by equation 2.
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There were no regions showing decreased deuterium incorporation after 2 h in the
presence of phenylalanine. Figure 3.5 compares the deuterium incorporation of different
peptides in the structure in the absence and presence of phenylalanine after 2 h. Figure
3.6 shows the locations in the structure of the peptides whose exchange was altered by
phenylalanine. Two of the eight peptides are in the regulatory domain. Peptide 39-59
includes the first helix, part of the first sheet and a small loop connecting them. Peptide
82-91 includes part of the second helix and a small loop closer to the N-terminus. The
increased deuterium uptake of these peptides suggests that the regulatory domain
becomes more open in the presence of phenylalanine. The other six peptides lie in the
catalytic domain. The residues in the peptides 249-259, 306-317 and 370-376 are in the
interdomain regions between the regulatory and catalytic domains. The N-terminal
autoregulatory sequence extends into the cleft between peptides 306-317 and 249-259,
reaching over the loop 370-376. In addition, peptide 370-376 contacts the catalytic
domain of another monomer. Peptide 241-248 is a small strand adjacent to helix 249-259.
Peptide 164-174 is a loop close to residues 410-425 of the tetramerization domain.
Peptide 220-227 is a short loop on the back of the active site connecting helices 205-216
and 227-237; of the eight peptides, this one showed the smallest increase in deuterium
incorporation in the presence of phenylalanine. The increased deuterium incorporation in
these regions establishes that phenylalanine binding results in conformational changes.
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Figure 3.5. Comparison of deuterium incorporation of wild-type PheH in the absence
(left) and presence of phenylalanine (right) after 2 h. Peptides are color-labeled
according to the extent of deuterium uptake. The eight peptides showing dramatic
difference are marked with numbers. The full length PheH structures were constructed
with the pdb files of 2PHM and 2PAH. The active site is indicated by iron atom as an
orange sphere. The peptides showing significantly increased deuterium incorporation are
indicated in the right panel.
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Figure 3.6. The peptides showing increased deuterium incorporation in the presence of
phenylalanine. The structures in panel A and B, constructed with pdb files of 2PHM and
2PAH, represent the front and back views of PheH, respectively. The catalytic and
tetramerization domains are shown in surface with grey and cyan colors, respectively.
The regulatory domain is only shown in a monomer as a green cartoon. The peptides
sensitive to phenylalanine are shown in red.
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Similar HXMS experiments were conducted with wild-type PheH in the presence of
400 μM BH4. 22 peptides were identified in the presence of BH4, covering 57% of
protein sequence. None of peptides showed a change as significant as was seen in the
presence of phenylalanine, suggesting that BH4 binding does not change the structure
significantly from the resting form (Figure 3.7). Only three peptides of the eight showing
dramatic differences in the presence of phenylalanine, 82-91, 249-259 and 306-317,
were found in the presence of BH4. Peptide 164-174 was not identified, but a similar
peptide, 167-179, could be analyzed. The remaining peptides were not detected. Small
differences were seen in the H/D exchange patterns of peptides 85-112, 306-317. 356-
369 and 435-454.
H/D exchange of ∆117 PheH
To analyze the contribution of the regulatory domain to the effects of phenylalanine
on the dynamics of the catalytic domain, similar H/D exchanges were performed with
∆117PheH in the presence and absence of 5 mM phenylalanine. ∆117PheH lacks the
regulatory domain. Deuterium incorporation into the peptides of ∆117PheH was not
significantly affected by phenylalanine (Figure 3.8), suggesting the treatment of
∆117PheH with phenylalanine does not result in the significant conformational changes
seen in the wild-type enzyme. Peptides 192-213, 269-284, and 348-355 show small
decreases in deuterium incorporation, and peptide 446-454 shows a small increase in
deuterium incorporation. Peptide 167-178 displays slower exchange but reaches the
same maximum exchange.
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Figure 3.7. Deuterium incorporation into peptides of wild-type PheH in the absence (○, dashed line) and presence (●, solid line)
of BH4. Percent deuterium incorporation was calculated by dividing the observed deuterium incorporation by the number of
exchangeable peptides bonds in a peptide. There is no adjustment for back-exchange. For peptides 21-38 and164-174, since no
identical peptides identified in the presence of BH4, two peptides 19-38 and 167-179 are compared to them.
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Figure 3.8. Deuterium incorporation into peptides of ∆117PheH in the absence (○, dashed line) and presence (●, solid line) of
phenylalanine. Percent deuterium incorporation was calculated by dividing the observed deuterium incorporation by the number
of exchangeable peptides bonds in a peptide. There is no adjustment for back-exchange.
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Figure 3.9 compares the H/D exchange curves of the peptides sensitive to
phenylalanine in wild-type PheH to the same peptides in ∆117PheH. Peptide 164-174
was not detected in ∆117PheH, so peptide 167-178 was analyzed instead. The other five
peptides were detected. Only the deuterium incorporation curve in the absence of
phenylalanine is shown in Figure 3.9 for clarity. The exchange patterns of peptides 241-
248, 249-259 and 370-376 in ∆117PheH are similar to those in the wild-type enzyme in
the absence of phenylalanine. However, the deuterium incorporation level of peptide
306-317 in ∆117PheH is 10% higher than in wild-type enzyme in the absence of
phenylalanine after 1 min, close to the deuterium incorporation level after 16 min in the
wild-type enzyme in the presence of phenylalanine. The deuterium incorporation curve
of peptide 220-227 for ∆117PheH is between the curves for the wild-type enzyme in the
absence and presence of phenylalanine.
Similar HXMS experiments were done for ∆117PheH in the presence of 400 μM
BH4. A total of 23 peptides were identified covering 68% of protein sequence. Four
peptides of the eight showing dramatic difference in deuterium incorporation in the
presence of phenylalanine were identified in ∆117PheH, 220-227, 241-249, 249-259 and
306-317. Peptides 164-174 and 370-376 were not detected. No dramatic difference in the
deuterium incorporation pattern of most of the peptides of ∆117PheH was observed in
the presence of BH4 (Figure 3.10). Peptides 192-213 and 220-227 displayed small
decreases in deuterium incorporation in the presence of BH4, whereas peptides 180-191
and 249-259 displayed small increases.
80
80
80
0
0.2
0.4
0.6
0.8
1
1 10 100
220-227
0
0.2
0.4
0.6
0.8
1
1 10 100
241-248
0
0.2
0.4
0.6
0.8
1
1 10 100
249-259
0
0.2
0.4
0.6
0.8
1
1 10 100
306-317
0
0.2
0.4
0.6
0.8
1
1 10 100
370-376
Figure 3.9. Comparison of the deuterium incorporation of the peptides sensitive to
phenylalanine in wild-type PheH and ∆117PheH. The curves with symbol “○” and “●”
represent the data of wild-type PheH in absence and presence of phenylalanine,
respectively. The curve with symbol “▲” represents the data of ∆117PheH in absence of
phenylalanine.
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Figure 3.10. Deuterium incorporation into peptides of ∆117PheH in the absence (○, dashed line) and presence (●, solid line) of
BH4. Percent deuterium incorporation was calculated by dividing the observed deuterium incorporation by the number of
exchangeable peptides bonds in a peptide. There is no adjustment for back-exchange.
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H/D exchange of phosphorylated PheH
HXMS experiments were also conducted with phosphorylated PheH. A total of 28
peptides were indentified for phosphorylated PheH, covering 79% of the sequence. The
deuterium incorporation patterns of most peptides in phosphorylated PheH in the
presence of phenylalanine were not significantly affected by phenylalanine (Figure 3.11),
suggesting that phenylalanine binding triggers no global conformational changes in
phosphorylated PheH. Peptide 438-453 is the only one showing a significant difference
in deuterium incorporation pattern in the presence of phenylalanine. Peptides 27-43, 82-
91, 164-174 and 205-213 displayed slight differences after 30 min in the presence of
phenylalanine. Five of the eight peptides showing dramatic changes in the wild type
enzyme in the presence of phenylalanine were analyzed, whereas peptides 220-227, 241-
248 and 370-376 were not detected.
Figure 3.12 compares the deuterium incorporation patterns of those peptides whose
exchange kinetics in the unphosphorylated enzyme were altered by phenylalanine with
the results for the phosphorylated PheH. Only the curves for the phosphorylated PheH in
the absence of phenylalanine are shown for clarity. Peptides 241-248 and 370-376 were
not detected in phosphorylated PheH. Peptides 249-259 and 306-317, similar to most
other peptides in phosphorylated PheH, display similar exchange patterns to those in
unphosphorylated PheH in the absence of phenylalanine. However, peptides 39-59, 82-
91 and 164-174 show patterns that are more similar to those in unphosphorylated PheH
in the presence of phenylalanine. This result suggests that the conformational changes
induced by phosphorylation are similar but not identical to those associated with
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Figure 3.11. Deuterium incorporation into peptides of phosphorylated PheH in the presence (●, solid line) of phenylalanine.
Deuterium incorporation in the absence of phenylalanine is also indicated (○, dashed line). Percent deuterium incorporation was
calculated by dividing the observed deuterium incorporation by the number of exchangeable peptides bonds in a peptide. There is
no adjustment for back-exchange.
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Figure 3.12. Comparison of the deuterium incorporation of the peptides sensitive to
phenylalanine in unphosphorylated PheH and phosphorylated PheH. The H/D exchange
curves for unphosphorylated PheH in the absence (○) and presence (●) of phenylalanine
are also shown for comparison.
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89
phenylalanine activation.
Similar HXMS experiments were done for phosphorylated PheH in the presence of
400 μM BH4. A total of 28 peptides were identified covering 78% of the protein
sequence. Of the eight peptides showing differences in wild type PheH in the presence of
phenylalnine, only peptide 249-259 was detected, while peptides 241-248 and 370-376
were not identified. For the remaining five peptides, although the identical peptides were
not identified, similar peptides could be analyzed. Most peptides displayed no significant
difference in the deuterium incorporation pattern in the presence of BH4. Peptides 129-
143 and 217-239 displayed slight decreases (Figure 3.13).
Discussion
The available crystal structures of PheH with analogs of phenylalanine lack the
regulatory domain (72, 166). Although the comparison of these structures with the
substrate-free structure shows significant structural changes in the catalytic domain,
there is no direct evidence showing how the regulatory domain itself changes. In this
report, we demonstrate that both the regulatory and catalytic domains undergo
significant conformational changes in the presence of phenylalanine. Eight peptides are
more accessible to the solvent. These results support Shiman’s model that phenylalanine
binding converts PheH into an active form that is more open than the substrate-free
PheH (41, 42, 150).
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Figure 3.13. Deuterium incorporation into peptides of phosphorylated PheH in the absence (○, dashed line) and presence (●, solid
line) of BH4. Percent deuterium incorporation was calculated by dividing the observed deuterium incorporation by the number of
exchangeable peptides bonds in a peptide. There is no adjustment for back-exchange.
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An interesting finding in this research is that the interdomain regions of the
regulatory and catalytic domains are converted into more open structures in the presence
of phenylalanine, consistent with the previous proposal by Kobe et al. (8) that
phenylalanine binding alters the relative orientation of the two domains. A thermal
stability study using infrared spectroscopy also suggested that the conformational
changes associated with the activation of PheH by phenylalanine are mainly associated
with the changes in the tertiary/quaternary structure instead of the secondary structure
(170). Of the eight peptides showing altered deuterium incorporation in the wild-type
enzyme by phenylalanine, peptides 241-248, 249-259, 306-317 and 370-376 are in the
interdomain regions between the regulatory and catalytic domains. The altered
conformations of these regions may change the accessibility of the active site, allowing
substrate to bind more easily.
Peptides 241-248 and 249-259 include residues 247-251 that form hydrogen bonds
to BH4 (171). The altered conformation of these two peptides in the wild type enzyme in
the presence of phenylalanine may help binding of BH4. Compared to BH4, the binding
site for phenylalanine is deeper in the active site. Peptide 268-295 includes the three
main residues, Arg270, Thr278 and His285, directly interacting with phenylalanine. The
deuterium exchange of this peptide was low (about 10% at maximum) and unaffected by
phenylalanine. The reason for the unchanged deuterium exchange of this peptide could
be that the decreased deuterium incorporation resulted from phenylalanine binding may
be masked by the increase in deuterium incorporation caused by the opening of the
active site upon phenylalanine activation.
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A modeling experiment predicted molecular motions between the two hinge-
bending regions of 183-201 and 219-226 upon phenylalanine binding (11), consistent
with the effect of phenylalanine on the exchange kinetics of peptide 220-227. Peptide
220-227 is a short loop adjacent to the helix 227-237. In the model-derived structure
Cys237 is involved in contacts of the catalytic domain with the tetramerization and
regulatory domains of an adjacent subunit (40). These contacts may be responsible for
the transmission of the activating conformational change to the other subunit, explaining
the positive cooperativity observed in phenylalanine activation (8, 172). In our results,
the peptide containing Cys237 (peptide 234-239) does not show changed deuterium
incorporation in the presence of phenylalanine. This peptide is in a helix that may be too
rigid to exchange. However, loop 220-227, adjacent to the helix 227-237, does show
increased exchange in the presence of phenylalanine.
The N-terminal residues 19-30 of PheH extend over the active site, contacting with
residues in peptides 130-136, 249-252, 315-326 and 376-386 (8). This N-terminal
sequence is proposed to play an autoinhibitory role, partially covering the active site;
phenylalanine binding would displace this sequence from the active site (8). Our results
found increased deuterium incorporation into peptides 241-248, 249-259, 306-317, and
370-376 in the presence of phenylalanine. These peptides are either in or adjacent to the
regions contacting the autoregulatory sequence. Peptide 164-174 is close in space to
peptide 130-136. The increased deuterium incorporation into these peptides, suggesting
exposure of these regions to solvent in the presence of phenylalanine, is consistent with
the proposed function of the N-terminal autoregulatory sequence. Two peptides in the N-
95
terminal autoregulatory sequence show no difference in the presence of phenylalanine.
Peptide 3-11 reached maximum exchange (over 90% if adjusted for back-exchange)
after 1 min in the absence of phenylalanine, suggesting a mobile conformation,
consistent with this peptide being absent in the crystal structure. Peptide 21-38, a long
flexible loop plus a small part of β-strand, reached maximum exchange after 2 min.
Given the fact that both peptides are highly mobile, the displacement of them would not
be reflected in increased deuterium exchange.
Of all the eight peptides, peptide 370-376 displayed the largest difference in the
presence of phenylalanine, with not only higher maximum deuterium incorporation but
also a dramatically slower exchange rate. Figure 3.5 shows that this peptide is close to
both the N-terminus and to the catalytic domain of another subunit. The dramatically
different deuterium incorporation pattern of peptide 370-376 in the presence of
phenylalanine suggests that this peptide interacts with the N-terminal 18 residues that are
missing in the structure of PheH. Alternatively, peptide 370-376 may transmit the
conformational change initiated by the displacement of the N-terminal sequence to the
other subunit. Peptide 370-376 is close to the loop 356-390 in the other subunit; the
latter sequence contacts with the N-terminus of that subunit. This provides another
possible mechanism for the conformational changes to be transmitted between the
catalytic domains of adjacent subunits, besides the possible contacts between the
regulatory and catalytic domains of different subunits through Cys237. The present
results suggest that the N-terminus forms a network of interactions with the active site,
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the regulatory domain and the adjacent subunit, initiating and transmitting the
conformational changes caused by phenylalanine.
Three peptides, 85-112, 129-143 and 205-213 displayed small increases in
deuterium incorporation in the presence of phenylalanine (Figure 3.3). Peptide 85-112
includes peptide 82-91, one of the peptides showing dramatically increased deuterium
incorporation in the presence of phenylalanine. The relatively small increase of this
peptide compared to peptide 82-91 suggests that the residues 92-112 are not affected by
phenylalanine. The increased exchange of peptides 129-143 and 205-213 is small
enough that we are reluctant to conclude that it reflects a significant conformational
change.
The coverage of wild type PheH in the presence of BH4 (Figure 3.7) is less than in
the presence of phenylalanine. Three of the eight peptides sensitive to phenylalanine, 82-
91, 249-259 and 306-317, were detected but did not show any significant difference. The
other five peptides were not detected reliably. Peptides 241-248 and 249-259 include
residues 247-251 which form hydrogen bonds to BH4 (171). Peptide 241-248 was not
detected in the wild type enzyme in the presence of BH4. The reason for the absence of
this peptide could be that binding of BH4 changes the local conformation and shields the
pepsin cleavage site. The deuterium incorporation into peptide 249-259 is also low in the
absence of BH4, suggesting that most amide hydrogens of this peptide are involved in
interactions that do not exchange. BH4 binding may form interactions with these amide
hydrogens instead of the free ones; therefore there was no decreased deuterium
incorporation observed in the presence of BH4 in peptide 249-259. None of the 22
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peptides displayed a dramatic difference in the presence of BH4, except that peptides 21-
38 and 85-112 showed slightly more exchange in the first min. These results show that
about 60% of residues in PheH have no significant conformational change in the
presence of BH4, consistent with the basically unchanged crystal structures of PheH
upon binding BH4 (10). However, since about 40% of the residues are absent from the
analysis, the possibility of some regions exhibiting conformational changes can not be
excluded.
∆117PheH has the same Vmax value as the wild-type enzyme and a lower Km for
phenylalanine. In addition, there is no lag in tyrosine production if the assay is started by
adding phenylalanine (150). These kinetics suggest that this truncated mutant behaves
similarly to the phenylalanine-activated wild-type enzyme. ∆117PheH lacks the N-
terminal sequence. If the increased deuterium incorporation found in the wild-type PheH
in the presence of phenylalanine is due only to the displacement of the N-terminal
sequence, then similar deuterium incorporation should be seen in ∆117PheH as in the
wild-type enzyme in the presence of phenylalanine. Figure 3.9 shows that only peptide
306-317 in ∆117PheH has the same maximum deuterium incorporation as in the wild-
type enzyme in the presence of phenylalanine, while peptides 241-248, 249-259 and
370-376 have exchange patterns indistinguishable from those in wild-type enzyme in the
absence of phenylalanine. The exchange pattern of peptide 220-227 in ∆117PheH is
intermediate between the patterns in wild-type enzyme in the absence and presence of
phenylalanine. These results suggest that simple displacement of the N-terminal
sequence is not the only reason for the altered exchange of the eight peptides in wild-
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type enzyme. There must be some other changes that make these regions more open, and
these changes require the regulatory domain. It could be the simple reorientation of the
regulatory and catalytic domains, since all these exposed regions are interdomain areas.
It also could be a series of complex conformational changes that start as a local change
caused by phenylalanine binding and are then transmitted to other parts or domains
through the net of interactions formed by N-terminal sequence. In general, our results
with ∆117PheH demonstrate that the increased deuterium incorporation of the eight
peptides in wild-type enzyme upon binding phenylalanine can not be attributed simply to
the displacement of the N-terminal sequence.
The results in Figure 3.8 suggest that although phenylalanine does not have a global
effect on the conformation of ∆117PheH, it still may cause some small local changes.
For example, the peptides 192-213, 269-284 and 348-355 become slightly less accessible
to solvent in the presence of phenylalanine. The reason for the small changes in peptide
192-213 is unclear. Peptides 269-284 and 348-355 include residues interacting with
phenylalanine, i.e., Arg270, Thr278, Ser349, Gly346, Ser350 and Glu353 (13).
Therefore, the small decreased deuterium incorporation could be regarded as local
changes due to binding of phenylalanine. The reason for the absence of the small
decreased deuterium incorporation of these two peptides in the wild type enzyme in the
presence of phenylalanine may be that the large scale conformational changes toward an
open structure counteract the small decreases caused by phenylalanine binding.
Some small differences in deuterium incorporation into ∆117PheH were also seen
in the presence of BH4 (Figure 3.10). Peptides 180-191 and 249-259 show slightly
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decreased deuterium incorporation, while peptides 192-213 and 220-227 show slightly
increased deuterium incorporation. Peptide 249-259 includes the residues Ser251,
Phe254 and Leu255 that form contacts with BH4 (171), which explain the protection
from exchange. Similar to the result that no difference in exchange is seen in the
phenylalanine binding site in the intact enzyme in the presence of phenylalanine, there is
also no decreased exchange in peptide 249-259 in the intact enzyme in the presence of
BH4. These results suggest that the regulatory changes have a dominant effect on the
conformations of PheH over the local effects caused by substrate binding. Decreased
deuterium incorporation into peptide 180-191 of ∆117PheH was also seen in peptide
183-191 of the wild type PheH in the presence of BH4. The reason is unclear. Peptides
192-213 and 220-227 are far from the binding site of BH4 in space, and they were not
identified in the wild type PheH in the presence of BH4. Therefore it is hard to know
their roles in the regulation by BH4.
Phosphorylation and phenylalanine activation have been reported to work in
concert to activate the enzyme. Phenylalanine-treated PheH is easier to phosphorylate
and phosphorylated PheH needs less phenylalanine to be activated (28, 146).
Phosphorylation does not result in a large-scale conformational change, based on the
crystal structures of the phosphorylated and unphosphorylated PheH. Instead, it has been
proposed that phosphorylation induces a limited conformational change around the
phosphoserine (8, 161). A hypothesis explaining the synergy of phenylalanine activation
and phosphorylation is that phosphorylation could stabilize the phenylalanine-activated
enzyme through electrostatic interaction of phosphoserine with the catalytic core (8,
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157). The absence of the N-terminal 18 residues in the crystal structures of the
phosphorylated and unphosphorylated PheH makes it hard to know how the local
structure changes around Ser16. Comparison of the deuterium exchange of these two
forms of PheH in Figure 3.12 provides the opportunity to explore the structural effect of
phosphorylation. The kinetics of deuterium exchange into peptides 39-59, 82-91 and
164-174 are intermediate between the kinetics of the unphosphorylated enzyme in the
absence of phenylalanine and in the presence of phenylalanine. However, the exchange
kinetics of peptides 249-259 and 306-317 are not affected by phosphorylation. Based on
these results, it seems that phosphorylation mainly affects the conformation of the
regulatory domain. Peptides 39-59 and 82-91 are not adjacent to Ser16 in the sequence,
which suggests the conformational changes induced by phosphorylation are not
restrained to the regions around the phosphoserine. The intermediate kinetics of
deuterium incorporation into peptides 39-59, 82-91 and 164-174 in the phosphorylated
PheH in the absence of phenylalanine implies that phosphorylation shifts the regulatory
domain and part of catalytic domain into an intermediate conformation close to that of
the phenylalanine-activated enzyme, consistent with the decreased amount of
phenylalanine required for activation. These results suggest the mechanism of activation
by phosphorylation is similar to but not identical to that of phenylalanine activation.
Our results provide evidence for the proposal that PheH is converted into an open
form upon binding phenylalanine. The results support the model that phenylalanine
activation displaces the N-terminal autoinhibitory sequence from the active site and that
a reorientation of the regulatory and catalytic domain takes place upon phenylalanine
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activation. Phosphorylation at Ser16 changes the regulatory domain of PheH into a
similar but not identical conformation as in the phenylalanine-activated form. Although
the details of regulation mechanisms of PheH remain unclear, these results provide a
better understanding of the structural basis of regulation.
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CHAPTER IV
PURIFICATION AND CHARACTERIZATION OF THE REGULATORY DOMAIN
OF PHENYLALANINE HYDROXYLASE
Phenylalanine hydroxylase (PheH) catalyzes the hydroxylation of phenylalanine
into tyrosine, the initial and rate-limiting step of the catabolic pathway of phenylalanine,
using enzyme-bound iron, molecular oxygen and tetrahydropterin (173, 174).
Dysfunctions of PheH due to mutations in the human PheH gene cause the serious
disease phenylketonuria (PKU), a common disorder in amino acid metabolism. PheH
belongs to the aromatic amino acid hydroxylase family that has two other members,
tyrosine hydroxylase (TyrH) and tryptophan hydroxylase (TrpH). TyrH and TrpH
catalyze the hydroxylation of tyrosine and tryptophan in the biosynthesis of
catecholamines and serotonin, respectively (81). PheH, TyrH and TrpH, are
homotetramers with each subunit consisting of an N-terminal regulatory domain, a
catalytic domain and a C-terminal tetramerization domain. The catalytic domain of PheH
contains the iron atom responsible for catalysis and determines the substrate specificity
(99). The three amino acid hydroxylases are 52% identical in the catalytic domains.
The regulatory domain of PheH, the N-terminal 117 residues, is involved in
regulation. The major mechanisms of regulation of PheH are activation by phenylalanine,
inhibition by BH4, and additional activation by phosphorylation (18). PheH can also be
activated by proteolysis, lysolecithin and thiol-modification agents (175). The
phosphorylation site in PheH is Ser16 in the regulatory domain. The activation by
phosphorylation of PheH is believed to work in concert with activation by phenylalanine
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(28). It is reported that phosphorylation does not affect the Vmax but instead decreases the
amount of phenylalanine required to activate PheH (27, 28). The bacterial form of PheH
from Chromabacterium violaceum that lacks the regulatory domain cannot be activated
by phenylalanine. This suggests that all three regulatory processes require the regulatory
domain. Both PheH and TyrH are activated by phosphorylation. However, TyrH is not
activated by its amino acid substrate or lysolecithin treatment. In contrast, it can be
activated by heparin (176). The dramatically different regulatory properties of TyrH and
PheH are consistent with the low identity of their regulatory domains (60).
Only one crystal structure of PheH includes the regulatory domain, that of dimeric
rat PheH lacking the C-terminal 24 residues (8). The regulatory domain of PheH is an α-
β sandwich, forming an interlocking double βαβ motif (βαββαβ) motif. This domain is
composed of a four-stranded antiparallel β-sheet flanked on one side by two short α-
helices and on the other side by segments 118-131 and 409-422 of the catalytic domain.
This structure shows that the N-terminus (residues 19-33) extends over the entrance of
the active site of the catalytic domain, contacting residues 130-136, 249-252, 315-326
and 376-379. This sequence is proposed to exert an autoinhibitory function by partly
covering the active site in the absence of phenylalanine (8). This proposed function is
supported by the observation that truncated PheH lacking the N-terminal sequence does
not require activation by phenylalanine and is not inhibited by BH4 (23, 150).
It has been postulated that there exist two phenylalanine binding sites in PheH (20).
Native PheH has been reported to bind 1.5 mol of phenylalanine/mol of subunit. After
treatment with N-ethylmaleimide, PheH binds about 1 mol of phenylalanine/mol of
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subunit. This modification activates PheH in a way that resembles the activation by
proteolysis, for example, shifting the binding curve of phenylalanine from sigmoid to
hyperbolic (20). The activating phenylalanine remains at the allosteric regulatory site
during catalytic turnover and, while there, cannot be hydroxylated (146). These results
provide evidences for two separate phenylalanine binding sites, a regulatory site and a
catalytic site (18). The thiol-modification site of PheH was later identified as Cys237
(34), which is positioned in the dimer interface, near to the interface of the catalytic and
regulatory domains (8). In a modeled structure of full-length hPheH, Cys237 is close to
residues in the oligomerization and regulatory domains of an adjacent subunit in the
dimer, especially Arg68 (172). This raises the possibility that the regulatory binding site
of phenylalanine may be located near to the interface of the catalytic and regulatory
domains. The conformational changes upon phenylalanine binding may modify the
relative orientation of the regulatory and catalytic domains, which could be stabilized by
phosphorylation, displacing the N-terminal inhibitory sequence away from the active site
(8).
The only structure with the regulatory domain is rat PheH including the regulatory
and catalytic domains (ΔCOOH430) in the phosphorylated and dephosphorylated states
with ferric iron (PDB 1PHZ and 2PHM) (8). The only structures of PheH with
phenylalanine analogues bound are those of the catalytic domain (PDB 1KW0, 1MMT)
(11). Therefore the present PheH structures cannot establish the existence of a regulatory
site of phenylalanine in the regulatory domain. There is no crystal structure of TyrH
including the regulatory domain. Little is known about the structure of the regulatory
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domain of TyrH, although it has been purified (69). In order to test the proposal of a
regulatory binding site of PheH, we expressed and purified the regulatory domain of
PheH. This research describes the design, expression, purification and some structural
studies on the regulatory domain of PheH.
Materials and Experimental Procedures
Materials
Leupeptin and pepstatin A were from Peptides Institute, Inc. (Osaka, Japan).
Restriction and DNA modification enzymes were purchased from New England Biolabs
(Ipswich, MA). 15NH4Cl was purchased from Cambridge isotope Laboratories, Inc
(Andover, MA). Thiamine hydrochloride, imidazole, carbonic anhydrase (from bovine
erythrocytes), cytochrome c (from horse heart) and thrombin (from bovine plasma) were
from Sigma-Aldrich (St. Louis, MO). Biotin and hemoglobin (from bovine blood) were
from USB (Cleveland, Ohio). The FPLC system used was an ÄKTA purifier (GE
Healthcare life science, Piscataway, NJ). The pET21b and pET28a were purchased from
Novagen (Madison, WI).
Construction for the expression of the regulatory domain of rat PheH
To construct a plasmid coding for the regulatory domain of rat PheH, a unique NcoI
site was introduced to the wild-type rat phenylalanine hydroxylase cDNA-containing
plasmid pERPH5 (99) to stop translation before residue 118. Plasmid pERPH5 was
subjected to mutagenesis using the oligonucleotide 5’-aag gaa aag aac aca tga CCATGG
ttc ccg cgg acc-3’. Site-directed mutagenesis was carried out with the Stratagene
QuikChange Kit using Pfu DNA polymerase. QIAfilter plasmid midi prep kits and
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QIAprep Spin miniprep kits were used for purifying plasmids, which were used to
transfect OmniMax competent cells (Invitrogen, Carlsbad, California). Oligonucleotide
synthesis and mutant DNA sequencing were conducted by Nucleic Acids Core Facility,
The University of Texas Health Science Center.
In order to get better expression, the gene coding for the regulatory domain of rat
PheH was moved to pET21b from the pET23d vector of pERPH5 containing the above
mutation. A fragment including the gene for the regulatory domain was generated by
PCR using the mutant as the template. The oligonucleotide 5’- gg gaa ttc CATATG gca
gct gtt gtc ctg gag aat gga -3’ was used as the 5’ primer to cover the start codon for the
regulatory domain gene and create a new NdeI cut site. Another oligonucleotide, 5’- ccg
CTCGAG tca tgt gtt ctt ttc ctt gtc tcg -3’, was used as the 3’ primer that includes a stop
codon and also creates a new XhoI cut site. After purification from agarose gels, the
PCR fragment encoding the regulatory domain gene was ligated to the empty vector
generated by digestion of pET21b by NdeI and XhoI using T4 DNA ligase. Possible
recombinants were screened by restriction enzyme analysis to rule out vector self
ligation. One positive clone was sequenced to confirm that the cDNA for the regulatory
domain of phenylalanine hydroxylase was inserted between the NdeI and XhoI sites of
pET21b. This plasmid was named pETRD, encoding the protein PheH1-117.
Similar procedures were conducted using the PCR fragment encoding for the
regulatory domain gene and the empty vector generated by digestion of pET28a by NdeI
and XhoI to generate a recombinant protein of the regulatory domain of PheH with a 6-
histidine tag at the N-terminus. The histidine-tag can be removed by thrombin digestion,
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leaving three extra residues (Gly-Ser-His) at the N-termini. This was pEThisRD,
encoding the protein hisPheH1-117.
Expression and purification of PheH1-117
E. coli strain C41(DE3) transformed with the plasmid pETRD was grown overnight
at 37 °C in Luria-Bertani medium plus 100 μg/mL ampicillin. Expression was induced
by addition of 0.25 mM isopropyl β-D-thioglucanopyranoside (IPTG) when the A600
reached 0.8-1.0. After 12-15 h, cells were harvested by centrifugation at 6000 × g for 30
min. Cell pellets were suspended in 50 mM Hepes, 0.2 M NaCl, 1 μM leupeptin, 1 μM
pepstatin A, 100 μg/ml lysozyme, and 100 μg/ml phenylmethylsulfonyl fluoride (PMSF),
pH 7.5. The cell suspension was sonicated using four bursts of 30 s at 45 W with 30 s
intervals, and then centrifuged at 30,000 × g for 30 min. The supernatant was treated
with ammonium sulfate. The protein precipitating between 60 and 80% saturation was
collected and dissolved in 50 mM Hepes, 0.5 mM EDTA, 10% glycerol, 1 μM leupeptin,
and 1 μM pepstatin A, pH 7.5. After dialysis in the same buffer with three buffer-
changes at 4 h intervals, the protein was applied to a 2.5 × 14-cm column of Q-
Sepharose equilibrated with the same buffer. The column was washed with 150 ml of the
same buffer, and the protein was eluted with a 500 ml gradient of the same buffer
containing 0-0.2 M NaCl. The fractions were assayed by SDS-polyacrylamide gel
electrophoresis. Those fractions showing a band with an apparent molecular weight of
13,000 were pooled and concentrated using an Amicon Ultra centrifugal filter (10,000
MWCO, Millipore). The concentrated sample was then applied to a HiPrep 16/60
Sephacryl S-100 HR (GE Healthcare Life Science, Piscataway, NJ) gel filtration column
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in 50 mM Hepes, 0.2 M NaCl, 0.5 mM EDTA, 1 μM leupeptin and 1 μM pepstatin A,
pH 7.5. The fractions were assayed by SDS-polyacrylamide gel electrophoresis. Those
exhibiting a single band with an apparent molecular weight of 13,000 were pooled and
stored at -80°C.
Expression and purification of 15N-labeled hisPheH1-117
To prepare 15N labeled protein for NMR, the plasmid pEThisRD was transformed
into BL21(DE3). One liter of autoinducing minimal medium used for expression was
made from 1 g 15NH4Cl, 50 mg kanamycin, 50 mM Na2HPO4, 50 mM KH2PO4, 5 mM
Na2SO4, 2 mM MgSO4, 0.5% glycerol, 0.05% glucose, 0.2% lactose and 0.5 × trace
metals, pH7.5 (177). Yeast extract (0.02%, w/v), 1 μg/ml thiamine hydrochloride and 1
μg/ml biotin were added to improve expression. All the components were autoclaved for
sterilization, except that thiamine hydrochloride, biotin, trace metals and kanamycin
were sterilized using a 0.22 μm syringe filter (Millipore, Bedford, MA). A freshly
transformed single colony was inoculated into 100 ml autoinducing minimal medium;
the culture was left shaking at 300 rpm overnight at 37°C. This culture was then diluted
into 900 ml of the same medium and kept shaking at 37°C for 5-8 h until the A600
reached saturation (about 2.6-2.8). Then the temperature was adjusted to 25°C to express
the target protein. After 18-24 h, the cells were harvested by centrifugation at 6000 × g
for 30 min. Cell pellets were suspended in 20 mM sodium phosphate buffer, 0.5 M NaCl,
5 mM imidazole, 1 μM leupeptin, 1 μM pepstatin A, 100 μg/ml lysozyme, and 100
μg/ml PMSF, pH 7.5. The cell suspension was sonicated using four bursts of 30 s at 45
W with 30 s intervals, then centrifuged at 30,000 × g for 30 min. The supernatant was
109
applied to a Histrap FF column (5 ml, GE Healthcare Life Science). A linear gradient of
50-300 mM imidazole in 10 column volumes of 20 mM sodium phosphate buffer, 0.5 M
NaCl, pH 7.5, was used to elute the target protein after washing the column with 5
column volumes of 50 mM imidazole in the same buffer. The absorbance of the eluted
fractions was monitored continuously at 280 nm. The peak fractions, hisPheH1-117, were
pooled and concentrated using an Amicon Ultra centrifugal filter (10,000 MWCO,
Millipore, Bedford, MA). The concentrated hisPheH1-117 protein was dialyzed in 20 mM
sodium phosphate buffer, 5% glycerol, 1 μM leupeptin, 1 μM pepstatin A, pH 7.5, with
3 buffer-changes at 2 h intervals.
Thrombin digestion
For the NMR analysis, the hisPheH1-117, was cleaved by thrombin. Thrombin (0.2
unit/μl) was added to a protein solution, approximate 1 mg/ml, to reach a ratio of 4 unit
thrombin per mg recombinant protein. The mixture was gently shaken overnight at 4°C,
followed by purification on a HiPrep 16/60 Sephacryl S-100 HR gel filtration column as
described above for the regulatory domain without the histidine tag.
Analytic gel filtration
The molecular weight of PheH1-117 was determined using a HiPrep 16/60 Sephacryl
S-100 HR gel filtration column in 50 mM Hepes, 0.2 M NaCl, 0.5 mM EDTA, 1 μM
leupeptin and 1 μM pepstatin A, pH 7.5, at room temperature. The flow rate was 0.8
ml/min and the absorbance of the eluate was monitored continuously at 280 nm. The
standards used were hemoglobin (66,000), carbonic anhydrase (29,000) and cytochrome
c (12,500).
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NMR spectroscopy and data processing
Samples for NMR containing 0.69 mM 15N-labelled regulatory domain were
prepared in 20 mM sodium phosphate buffer, 5% glycerol, pH 7, in 95% H2O/5% D2O.
All NMR data were collected at 308 K on a Bruker 700 MHz spectrometer. The 1H-15N
HSQC (heteronuclear single-quantum coherence) spectrum was recorded without any
ligands and with 5 mM phenylalanine or 5 mM proline. NMR data was processed using
NMRpipe and visualized using NMRDraw (178).
Results
Expression and purification of PheH1-117 and hisPheH1-117
To obtain the regulatory domain of PheH, a mutation replacing Val118 with a stop
codon was introduced into the plasmid pERPH5 encoding the wild type rat PheH.
However, the mutant protein expressed poorly in C41(DE3) cell. Consequently, a DNA
fragment including the gene encoding PheH1-117 with NdeI and XhoI cut sites at the 5’
and 3’ ends, respectively, was generated by PCR using this construct as the template.
This was ligated into pET21b to yield pETRD. PheH1-117 expressed well in C41(DE3)
cells, reaching approximately 5% of the total protein, and the protein was soluble. Most
proteins under 25 kD, including about one tenth of PheH1-117, were precipitated after
treatment with 60% saturated ammonium sulfate (data not shown). The majority of
PheH1-117 was precipitated when the ammonium sulfate concentration was increased to
80%. PheH1-117 eluted from the Q-Sepharose column between 40 and 100 mM NaCl.
The Q-Sepharose column removed most contaminating proteins, leaving four that have
higher molecular weights than PheH1-117 (Figure 4.1).
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Figure 4.1. SDS-polyacrylamide gel electrophoresis of samples obtained during
purification of the regulatory domain of PheH. The gel contained 15% (w/v)
polyacrylamide. Lane 1, molecular mass standards in kDa; lane 2, concentrated sample
after precipitating between 60 and 80% saturated ammonium sulfate (dialyzed); lane 3,
concentrated sample after the Q-Sepharose column; lane 4, eluate from the gel filtration
column.
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A subsequent gel filtration column yielded PheH1-117 of over 95% purity. The yield
from 1 liter of cell culture was 3-5 mg. The single band on SDS-polyacrylamide gel
corresponding to PheH1-117 was sent to the Institutional Mass Spectrometry Laboratory
of The University of Texas Health Science Center for identification. Twelve unique
peptides generated by trypsin digestion covered 114 of the 117 residues, confirming the
protein as PheH1-117.
The pure PheH1-117 protein is not very stable. It is usually stored at pH 7.0-7.5, 4 °C.
At pH 6.5, the concentrated protein will precipitate. Multiple freeze-and-thaw cycles
also precipitate this protein. Therefore the protein used in this study was freshly purified
or thawed only once to avoid precipitation. The presence of phenylalanine seemed to
stabilize the protein, but this property was not characterized further.
The supernatant of the cell lysate including PheH1-117 was applied to a Phenyl-
Sepharose column in the presence of phenylalanine followed by elution with buffer
without phenylalanine. Subsequent SDS-polyacrylamide gel electrophoresis showed that
PheH1-117 protein did not bind to the column (data not shown).
The hisPheH1-117 did not express well in regular M9 minimal medium. However, it
was efficiently expressed in the autoinducing minimal medium at 37 °C. Unfortunately,
the hisPheH1-117 expressed at 37 °C was completely insoluble. If cells were grown at 25
°C, about 40% of the recombinant protein was soluble. When the growth temperature
decreased to 16 °C, the protein expressed poorly. The hisPheH1-117 grown at 25 °C was
over 95% pure after purification on a Histrap FF column. The yield of hisPheH1-117 was
5-8 mg from 1 liter of cell culture. An SDS-polyacrylamide gel showed that thrombin
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efficiently removed the histidine tag (data not shown). A subsequent purification using a
gel filtration column separated the target protein from the thrombin.
Analytical gel filtration
The retention time of the regulatory domain of PheH on a gel filtration column was
between carbon anhydrase (29 kD) and cytochrome c (12.5 kD) and close to the former
(Figure 4.2). The molecular weight for the monomer of PheH1-117 based on its sequence
is 13.2 kD. The molecular weight of PheH1-117 was determined as about 26 kD based on
the result of analytical gel filtration. This suggests that the regulatory domain of PheH is
a dimer in solution.
The retention time of the regulatory domain of PheH on gel filtration column in the
presence of phenylalanine (5 mM) was significantly earlier than that for protein alone
(Figure 4.3). This suggests that phenylalanine binds to and changes the conformation of
the regulatory domain of PheH. As a control, a similar experiment was done in the
presence of 5 mM proline. Proline has been reported not able to activate PheH (179).
The retention time was not changed from that for the protein alone.
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Figure 4.2. Gel filtration chromatography of the regulatory domain of PheH (PheH1-117).
The protein standards were hemoglobin (66 kD), carbonic anhydrase (29 kD) and
cytochrome c (12.5 kD).
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Figure 4.3. Gel filtration chromatography of the regulatory domain of PheH alone
(dotted line) or with 5 mM phenylalanine (solid line) or 5 mM proline (dashed line).
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NMR spectroscopy
The 1H-15N HSQC spectrum of PheH1-117 at pH 7.0 and 308 K is shown in Figure 4.4.
Chemical shift perturbation was used to monitor the effect of phenylalanine on PheH1-117.
In the absence of phenylalanine, about 120 peaks could be seen in the spectrum. Most
cross peaks are broad and weak, and some peaks with 1H chemical shift between 7.8 and
8.5 ppm overlap. After the addition of 5 mM phenylalanine, fewer peaks are seen in the
spectrum and most of the remaining peaks are stronger and sharper (Figure 4.4A). Some
peaks are lost, with others shown at new positions, as indicated with black and green
arrows in Figure 4.4B, respectively. Meanwhile, the peaks that do not shift and become
more intense and clear are indicated with red arrows. The NMR spectrum of PheH1-117 in
the presence of 5 mM proline is the same as that of the protein alone (Figure 4.4A).
These results suggest that phenylalanine interacts with PheH1-117 and causes a significant
conformational change.
Discussion
In this study, the regulatory domain of PheH, PheH1-117 was successfully expressed
and purified. In solution PheH1-117 is a dimer. One possible explanation for this
observation is that the interface between the regulatory and catalytic domains is large
and hydrophobic; the hydrophobic surfaces of two regulatory domains are prone to
interact with each other in the absence of the catalytic domain. Figures 4.3 and 4.4 show
that PheH1-117 changes conformation in the presence of phenylalanine. These results
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Figure 4.4. NMR spectra of PheH1-117. 15N HSQC NMR spectra of the 15N-labeled PheH1-117 alone (a), in the presence of 5 mM
phenylalanine (b) or 5 mM proline (c) are shown in panel A. The boxed regions in panel A are shown in a larger view in panel
B. The black, red and green arrows indicate examples of peaks getting lost, stronger or showing up at new places, respectively
in the presence of phenylalanine.
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strongly support the proposal that there is a binding site for phenylalanine in the
regulatory domain of PheH. The full-length PheH can be purified using a Phenyl-
Sepharose column (22). This method is based on the observation that PheH undergoes
large-scale conformational changes, exposing a hydrophobic site that binds very tightly
to the hydrophobic chromatography support if the enzyme is activated by phenylalanine.
When phenylalanine is removed from the buffer, the enzyme desorbs from the support.
Our results show that PheH1-117 cannot be purified using the same method. Although
there are several hydrophobic residues in the regulatory domain interface with the
catalytic domain, they might be shielded in the dimer.
The regulatory domain of PheH is structurally similar to the regulatory domain of
phosphoglycerate dehydrogenase (PGDH). PGDH is allosterically inhibited by serine. In
the structure of the PGDH regulatory domain the binding site for the allosteric serine
coincides with the residues 65-69 in PheH. These residues are near the interface between
the regulatory and catalytic domains.This raises the possibility that phenylalanine could
bind to the interface of the regulatory and catalytic domains.
The study of H/D exchange in Chapter III indicated that the addition of
phenylalanine to the full-length PheH resulted in the increased solvent accessibility of
the interface region between the regulatory and catalytic domains. There is no peptide
identified in our study exactly covering residues 65-69. Two peptides near the two ends
of 65-69, 39-59 (covering part of β strand Rβ1 and the whole helix Rα1) and 82-91
(covering part of helix Rα2), showed increased exchange in the presence of
phenylalanine, suggesting a more open conformation. Peptide 54-61 displayed slightly
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increased deuterium incorporation, while 67-81 showed no change. These results are
consistent with the finding here that there exists a binding site for phenylalanine in the
regulatory domain. It implies that the binding site of phenylalanine in the regulatory
domain has a larger effect on residues 39-59 and 54-61. Because residues 82-91 are
spacially close to helix Rα1, binding of phenylalanine could directly disrupt the
interaction of Rα1 and Rα2 and change the conformation of the regulatory domain.
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CHAPTER V
 SUMMARY
This study provides structural information to better understand the structure and
function of PheH. The active site of PheH contains a five/six-coordinated iron Fe(III)
with two/three labile water molecules, forming a 2-His-1-carboxylate facial triad. The
results in Chapter II revealed that this arrangement provides plasticity to the iron ligands
to optimize the active site for iron binding and amino acid hydroxylation. The results in
Chapter III suggest that PheH undergoes global conformational changes, including the
displacement of the N-terminus and reorientation of the regulatory and catalytic domains
upon activation by phenylalanine. Phosphorylation at Ser16 results in similar
conformational changes to those upon phenylalanine activation, but these changes are
localized in the vicinity of phosphorylation site. The binding of BH4 does not
significantly change the structure of PheH. The results in Chapter IV introduce the
method of purifying the regulatory domain of PheH, PheH1-117. The experiments of
analytical gel filtration and 1H-15N NMR spectroscopy suggest that PheH1-117 is a dimer
in solution and there is a phenylalanine binding site in the regulatory domain of PheH.
The overall information provided by this research expands the understanding of the
mechanism of activation of PheH by phenylalanine. Future work to determine where the
binding site is in the regulatory domain will help further elucidate this regulatory
mechanism.
121
REFERENCES
1. Woo, S. L., Güttler. F., Ledley, F. D., Lidsky, A. S., Kwok, S. C., DiLella, A. G.,
and Robson, K. J. (1985) The human phenylalanine hydroxylase gene, Prog. Clin.
Biol. Res. 177, 123-135.
2. Scriver, C. R., Hurtubise, M., Konecki, D., Phommarinh, M., Prevost, L.,
Erlandsen, H., Stevens, R., Waters, P. J., Ryan, S., McDonald, D., and Sarkissian,
C. (2003) PAHdb 2003: What a locus-specific knowledgebase can do, Hum.
Mutat. 21, 333-344.
3. Wallick, D. E., Bloom, L. M., Gaffney, B. J., and Benkovic, S. J. (1984)
Reductive activation of phenylalanine hydroxylase and its effect on the redox
state of the non-heme iron, Biochemistry 23, 1295-1302.
4. Kaufman, S. (1957) The enzymatic conversion of phenylalanine to tyrosine, J.
Biol. Chem. 226, 511-524.
5. Erlandsen, H., Fusetti, F., Martinez, A., Hough, E., Flatmark, T., and Stevens, R.
C. (1997) Crystal structure of the catalytic domain of human phenylalanine
hydroxylase reveals the structural basis for phenylketonuria, Nat. Struct. Biol. 4,
995-1000.
6. Fusetti, F., Erlandsen, H., Flatmark, T., and Stevens, R. C. (1998) Structure of
tetrameric human phenylalanine hydroxylase and its implications for
phenylketonuria, J. Biol. Chem. 273, 16962-16967.
7. Erlandsen, H., Flatmark, T., Stevens, R. C., and Hough, E. (1998)
Crystallographic analysis of the human phenylalanine hydroxylase catalytic
122
domain with bound catechol inhibitors at 2.0 Å resolution, Biochemistry 37,
15638-15646.
8. Kobe, B., Jennings, I. G., House, C. M., Michell, B. J., Goodwill, K. E.,
Santarsiero, B. D., Stevens, R. C., Cotton, R. G. H., and Kemp, B. E. (1999)
Structural basis of autoregulation of phenylalanine hydroxylase, Nat. Struct. Biol.
6, 442-448.
9. Erlandsen, H., Bjorgo, E., Flatmark, T., and Stevens, R. C. (2000) Crystal
structure and site-specific mutagenesis of pterin-bound human phenylalanine
hydroxylase, Biochemistry 39, 2208-2217.
10. Andersen, O. A., Flatmark, T., and Hough, E. (2001) High resolution crystal
structures of the catalytic domain of human phenylalanine hydroxylase in its
catalytically active Fe(II) form and binary complex with tetrahydrobiopterin, J.
Mol. Biol. 314, 279-291.
11. Andersen, O. A., Stokka, A. J., Flatmark, T., and Hough, E. (2003) 2.0 Å
Resolution crystal structures of the ternary complexes of human phenylalanine
hydroxylase catalytic domain with tetrahydrobiopterin and 3-(2-thienyl)-L-
alanine or L-norleucine: Substrate specificity and molecular motions related to
substrate binding, J. Mol. Biol. 333, 747-757.
12. Erlandsen, H., and Stevens, R. C. (1999) The structural basis of phenylketonuria,
Mol. Genet. Metab. 68, 103-125.
13. Andersen, O. A., Flatmark, T., and Hough, E. (2002) Crystal structure of the
ternary complex of the catalytic domain of human phenylalanine hydroxylase
123
with tetrahydrobiopterin and 3-(2-thienyl)-L-alanine, and its implications for the
mechanism of catalysis and substrate activation, J. Mol. Biol. 320, 1095-1108.
14. Kaufman, S. (1987) Phenylalanine 4-monooxygenase from rat liver, Methods
Enzymol. 142, 3-17.
15. Andersson, K. K., Cox, D. D., Que, L., Jr., Flatmark, T., and Haavik, J. (1988)
Resonance Raman studies on the blue-green-colored bovine adrenal tyrosine 3-
monooxygenase (tyrosine hydroxylase). Evidence that the feedback inhibitors
adrenaline and noradrenaline are coordinated to iron, J. Biol. Chem. 263, 18621-
18626.
16. Kappock, T. J., Harkins, P. C., Friedenberg, S., and Caradonna, J. P. (1995)
Spectroscopic and kinetic properties of unphosphorylated rat hepatic
phenylalanine hydroxylase expressed in Escherichia coli. Comparison of resting
and activated states, J. Biol. Chem. 270, 30532-30544.
17. Martinez, A., Knappskog, P. M., Olafsdottir, S., Doskeland, A. P., Eiken, H. G.,
Svebak, R. M., Bozzini, M., Apold, J., and Flatmark, T. (1995) Expression of
recombinant human phenylalanine hydroxylase as fusion protein in Escherichia
coli  circumvents proteolytic degradation by host cell proteases, Biochem. J. 306,
589-597.
18. Hufton, S. E., Jennings, I. G., and Cotton, R. G. H. (1995) Structure and function
of the aromatic amino acid hydroxylases, Biochem. J. 311, 353-366.
19. Shiman, R., and Gray, D. W. (1980) Substrate activation of phenylalanine
hydroxylase. A kinetic characterizaion, J. Biol. Chem. 255, 4793-4800.
124
20. Parniak, M. A., and Kaufman, S. (1981) Rat liver phenylalanine hydroxylase.
Activation by sulfhydryl modification, J. Biol. Chem. 256, 6876-6882.
21. Phillips, R. S., Parniak, M. A., and Kaufman, S. (1984) Spectroscopic
investigation of ligand interaction with hepatic phenylalanine hydroxylase:
Evidence for conformational change associated with activation, Biochemistry 23,
3836-3842.
22. Shiman, R., Gray, D. W., and Pater, A. (1979) A simple purification of
phenylalanine hydroxylase by substrate-induced hydrophobic chromatography, J.
Biol. Chem. 254, 11300-11306.
23. Jennings, I. G., Teh, T., and Kobe, B. (2001) Essential role of the N-terminal
autoregulatory sequence in the regulation of phenylalanine hydroxylase, FEBS
Letters 488, 196-200.
24. Wretborn, M., Humble, E., Ragnarsson, U., and Engstrom, L. (1980) Amino acid
sequence at the phosphorylated site of rat liver phenylalanine hydroxylase and
phosphorylation of a corresponding synthetic peptide, Biochem. Biophys. Res.
Commun. 93, 403-408.
25. Abita, J. P., Milstien, S., Chang, N., and Kaufman, S. (1976) In vitro activation
of rat liver phenylalanine hydroxylase by phosphorylation, J. Biol. Chem. 251,
5310-5314.
26. Doskeland, A. P., Schworer, C. M., Doskeland, S. O., Chrisman, T. D., Soderling,
T. R., Corbin, J. D., and Flatmark, T. (1984) Some aspects of the
125
phosphorylation of phenylalanine 4-monooxygenase by a calcium-dependent and
calmodulin-dependent protein kinase, Eur. J. Biochem. 145, 31-37.
27. Shiman, R., and Jefferson, L. S. (1982) Iron-dependent regulation of rat liver
phenylalanine hydroxylase activity in vivo, in vitro, and in perfused liver, J. Biol.
Chem. 257, 839-844.
28. Doskeland, A. P., Doskeland, S. O., Ogreid, D., and Flatmark, T. (1984) The
effect of ligands of phenylalanine 4-monooxygenase on the cAMP-dependent
phosphorylation of the enzyme, J. Biol. Chem. 259, 11242-11248.
29. Kowlessur, D., Yang, X.-J., and Kaufman, S. (1995) Further studies of the role of
Ser-16 in the regulation of the activity of phenylalanine hydroxylase, Proc. Natl.
Acad. Sci. 92, 4743-4747.
30. Citron, B. A., Davis, M. D., and Kaufman, S. (1994) Electrostatic activation of
rat phenylalanine hydroxylase, Biochem. Biophys. Res. Commun. 198, 174-180.
31. Shiman, R. (1980) Relationship between the substrate activation site and
catalytic site of phenylalanine hydroxylase, J. Biol. Chem. 255, 10029-10032.
32. Iwaki, M., Phillips, R. S., and Kaufman, S. (1986) Proteolytic modification of the
amino-terminal and carboxyl-terminal regions of rat hepatic phenylalanine
hydroxylase, J. Biol. Chem. 261, 2051-2056.
33. Fisher, D. B., and Kaufman, S. (1973) The stimulation of rat liver phenylalanine
hydroxylase by lysolecithin and α-chymotrypsin, J. Biol. Chem. 248, 4345-4353.
126
34. Gibbs, B. S., and Benkovic, S. J. (1991) Affinity labeling of the active site and
the reactive sulfhydryl associated with activation of rat liver phenylalanine
hydroxylase, Biochemistry 30, 6795-6802.
35. Knappskog, P. M., and Martinez, A. (1997) Effect of mutations at Cys237 on the
activation state and activity of human phenylalanine hydroxylase, FEBS Lett 409,
7-11.
36. Thorolfsson, M., Teigen, K., and Martinez, A. (2003) Activation of
phenylalanine hydroxylase: Effect of substitutions at Arg68 and Cys237,
Biochemistry 42, 3419-3428.
37. Chiappelli, F., Haggerty, D. F., Lynch, M., and Popjak, G. (1981) Translation of
phenylalanine hydroxylase-specific mRNA in vitro: Evidence for pretranslational
control by glucocorticoids, Proc. Natl. Acad. Sci. USA. 78, 2105-2109.
38. Shiman, R., Gray, D. W., and Hill, M. A. (1994) Regulation of rat liver
phenylalanine hydroxylase. I. Kinetic properties of the enzyme's iron and enzyme
reduction site, J. Biol. Chem. 269, 24637-24646.
39. Xia, T., Gray, D. W., and Shiman, R. (1994) Regulation of rat liver
phenylalanine hydroxylase. III. Control of catalysis by (6R)-tetrahydrobiopterin
and phenylalanine, J. Biol. Chem. 269, 24657-24665.
40. Rose, G. A., Lumb, F. H., and Dent, C. E. (1957) Discussion on generalized
aches and pains from metabolic bone disease, Proc. R. Soc. Med. 50, 371-380.
41. Folling, A. (1967) [Phenylketonuria], Tidsskr Nor Laegeforen 87, Suppl: 451-
454.
127
42. Paine, R. S. (1957) The variability in manifestations of untreated patients with
phenylketonuria (phenylpyruvic aciduria), Pediatrics 20, 290-302.
43. Ledley, F. D., Koch, R., Jew, K., Beaudet, A., O'Brien, W. E., Bartos, D. P., and
Woo, S. L. (1988) Phenylalanine hydroxylase expression in liver of a fetus with
phenylketonuria, J. Pediatr. 113, 463-468.
44. Scriver, C. R., and Kaufman, S. (2001) Hyperphenylalanemia: Phenylalanine
hydroxylase deficiency, in The metabolic and molecular bases of inherited
disease (Scriver, C. R., Beaudet, A. L., Sly, D. S., and Valle, D., Eds.), pp 1667-
1724, McGraw-Hill, New York.
45. Sarkissian, C. N., and Gamez, A. (2005) Phenylalanine ammonia lyase, enzyme
substitution therapy for phenylketonuria, where are we now?, Mol Genet Metab
86 Suppl 1, S22-26.
46. Kure, S., Hou, D. C., Ohura, T., Iwamoto, H., Suzuki, S., Sugiyama, N.,
Sakamoto, O., Fujii, K., Matsubara, Y., and Narisawa, K. (1999)
Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, J Pediatr
135, 375-378.
47. Wang, L., Surendran, S., Michals-Matalon, K., Bhatia, G., Tanskley, S., Koch, R.,
Grady, J., Tyring, S. K., Stevens, R. C., Guttler, F., and Matalon, R. (2007)
Mutations in the regulatory domain of phenylalanine hydroxylase and response
to tetrahydrobiopterin, Genet Test 11, 174-178.
48. Fang, B., Eisensmith, R. C., Li, X. H., Finegold, M. J., Shedlovsky, A., Dove, W.,
and Woo, S. L. (1994) Gene therapy for phenylketonuria: Phenotypic correction
128
in a genetically deficient mouse model by adenovirus-mediated hepatic gene
transfer, Gene Ther 1, 247-254.
49. Mochizuki, S., Mizukami, H., Ogura, T., Kure, S., Ichinohe, A., Kojima, K.,
Matsubara, Y., Kobayahi, E., Okada, T., Hoshika, A., Ozawa, K., and Kume, A.
(2004) Long-term correction of hyperphenylalaninemia by AAV-mediated gene
transfer leads to behavioral recovery in phenylketonuria mice, Gene Ther 11,
1081-1086.
50. Onishi, A., Liotta, L. J., and Benkovic, S. J. (1991) Cloning and expression of
Chromobacterium violaceum phenylalanine hydroxylase in Escherichia coli and
comparison of amino acid sequence with mammalian aromatic amino acid
hydroxylases, J. Biol. Chem. 266, 18454-18459.
51. Pember, S. O., Villafranca, J. J., and Benkovic, S. J. (1986) Phenylalanine
hydroxylase from Chromobacterium violaceum is a copper-containing
monooxygenase. Kinetics of the reductive activation of the enzyme,
Biochemistry 25, 6611-6619.
52. Carr, R. T., Balasubramanian, S., Hawkins, P. C. D., and Benkovic, S. J. (1995)
Mechanism of metal-independent hydroxylation by Chromobacterium violaceum
phenylalanine hydroxylase, Biochemistry 34, 7525-7532.
53. Chen, D., and Frey, P. (1998) Phenylalanine hydroxylase from Chromobacterium
violaceum. Uncoupled oxidation of tetrahydropterin and the role of iron in
hydroxylation, J. Biol. Chem. 273, 25594-25601.
129
54. Volner, A., Zoidakis, J., and Abu-Omar, M. M. (2003) Order of substrate binding
in bacterial phenylalanine hydroxylase and its mechanistic implication for pterin-
dependent oxygenases, J. Biol. Inorg. Chem. 8, 121-128.
55. Hagedoorn, P. L., Schmidt, P. P., Andersson, K. K., Hagen, W. R., Flatmark, T.,
and Martinez, A. (2001) The effect of the substrate, dihydrobiopterin and
dopamine on the EPR spectroscopic properties and the midpoint potential of the
catalytic iron in recombinant human phenylalanine hydroxylase, J. Biol. Chem.
276, 22850-22856.
56. Fitzpatrick, P. F. (1991) The steady state kinetic mechanism of rat tyrosine
hydroxylase, Biochemistry 30, 3658-3662.
57. Knappskog, P. M., Flatmark, T., Aarden, J. M., Haavik, J., and Martinez, A.
(1996) Structure/function relationships in human phenylalanine hydroxylase.
Effect of terminal deletions on the oligomerization, activation and cooperativity
of substrate binding to the enzyme, Eur. J. Biochem. 242, 813-821.
58. Panay, A. J., and Fitzpatrick, P. F. (2008) Kinetic isotope effects on aromatic and
benzylic hydroxylation by Chromobacterium violaceum phenylalanine
hydroxylase as probes of chemical mechanism and reactivity, Biochemistry 47,
11118-11124.
59. Erlandsen, H., Kim, J. Y., Patch, M. G., Han, A., Volner, A., Abu-Omar, M. M.,
and Stevens, R. C. (2002) Structural comparison of bacterial and human iron-
dependent phenylalanine hydroxylases: Similar fold, different stability and
reaction rates, J. Mol. Biol. 320, 645-661.
130
60. Fitzpatrick, P. F. (2003) Mechanism of aromatic amino acid hydroxylation,
Biochemistry 42, 14083-14091.
61. Siltberg-Liberles, J., Steen, I. H., Svebak, R. M., and Martinez, A. (2008) The
phylogeny of the aromatic amino acid hydroxylases revisited by characterizing
phenylalanine hydroxylase from Dictyostelium discoideum, Gene 427, 86-92.
62. Daubner, S. C., Melendez, J., and Fitzpatrick, P. F. (2000) Reversing the
substrate specificities of phenylalanine and tyrosine hydroxylase: Aspartate 425
of tyrosine hydroxylase is essential for L-DOPA formation, Biochemistry 39,
9652-9661.
63. Nagatsu, T., Levitt, M., and Udenfriend, S. (1964) Tyrosine hydroxylase: The
initial step in norepinephrine biosynthesis, J. Biol. Chem. 239, 2910-2917.
64. Haycock, J. W., Meligeni, J. A., Bennett, W. F., and Waymire, J. C. (1982)
Phosphorylation and activation of tyrosine hydroxylase mediate the
acetylcholine-induced increase in catecholamine biosynthesis in adrenal
chromaffin cells, J. Biol. Chem. 257, 12641-12648.
65. Haycock, J. W. (2002) Peptide substrates for ERK1/2: Structure function studies
of serine 31 in tyrosine hydroxylase, J. Neurosci. Methods 116, 29-34.
66. Kumer, S. C., and Vrana, K. E. (1996) Intricate regulation of tyrosine
hydroxylase activity and gene expression, J. Neurochem. 67, 443-462.
67. Grima, B., Lamouroux, A., Boni, C., Julien, J.-F., Javoy-Agid, F., and Mallet, J.
(1987) A single human gene encoding multiple tyrosine hydroxylases with
different predicted functional characteristics, Nature 326, 707-711.
131
68. Kaneda, N., Kobayashi, K., Ichinose, H., Kishi, F., Nakazawa, A., Kurosawa, Y.,
Fujita, K., and Nagatsu, T. (1987) Isolation of a novel cDNA clone for human
tyrosine hydroxylase:  Alternative RNA splicing produces four kinds of mRNA
from a single gene, Biochem. Biophys. Res. Commun. 147, 971-975.
69. Daubner, S. C., Lohse, D. L., and Fitzpatrick, P. F. (1993) Expression and
characterization of catalytic and regulatory domains of rat tyrosine hydroxylase,
Protein Sci. 2, 1452-1460.
70. Goodwill, K. E., Sabatier, C., Marks, C., Raag, R., Fitzpatrick, P. F., and Stevens,
R. C. (1997) Crystal structure of tyrosine hydroxylase at 2.3 Å and its
implications for inherited diseases, Nat. Struc. Biol. 4, 578-585.
71. Hegg, E. L., and Que, L. (1997) The 2-His-1-carboxylate facial triad - An
emerging structural motif in mononuclear non-heme iron (II) enxymes, Eur. J.
Biochem. 250, 625-629.
72. Quinsey, N. S., Lenaghan, C. M., and Dickson, P. W. (1996) Identification of
Gln313 and Pro327 as residues critical for substrate inhibition in tyrosine
hydroxylase, J. Neurochem. 66, 908-914.
73. Daubner, S. C., McGinnis, J. T., Gardner, M., Kroboth, S. L., Morris, A. R., and
Fitzpatrick, P. F. (2006) A flexible loop in tyrosine hydroxylase controls
coupling of amino acid hydroxylation to tetrahydropterin oxidation, J. Mol. Biol.
359, 299-307.
132
74. Daubner, S. C., and Fitzpatrick, P. F. (1998) Mutation to phenylalanine of
tyrosine 371 in tyrosine hydroxylase increases the affinity for phenylalanine,
Biochemistry 37, 16440-16444.
75. Ellis, H. R., Daubner, S. C., McCulloch, R. I., and Fitzpatrick, P. F. (1999)
Phenylalanine residues in the active site of tyrosine hydroxylase: Mutagenesis of
Phe300 and Phe309 to alanine and metal ion-catalyzed hydroxylation of Phe300,
Biochemistry 38, 10909-10914.
76. Ellis, H. R., Daubner, S. C., and Fitzpatrick, P. F. (2000) Mutation of serine 395
of tyrosine hydroxylase decouples oxygen-oxygen bond cleavage and tyrosine
hydroxylation, Biochemistry 39, 4174-4181.
77. Almas, B., Le Bourdelles, B., Flatmark, T., Mallet, J., and Haavik, J. (1992)
Regulation of recombinant human tyrosine hydroxylase isozymes by
catecholamine binding and phosphorylation structure/activity studies and
mechanistic implications, Eur. J. Biochem. 209, 249-255.
78. Daubner, S. C., Lauriano, C., Haycock, J. W., and Fitzpatrick, P. F. (1992) Site-
directed mutagenesis of serine 40 of rat tyrosine hydroxylase. Effects of
dopamine and cAMP-dependent phosphorylation on enzyme activity, J. Biol.
Chem. 267, 12639-12646.
79. Fitzpatrick, P. F. (1989) The metal requirement of rat tyrosine hydroxylase,
Biochem. Biophys. Res. Commun. 161, 211-215.
133
80. Ramsey, A. J., Hillas, P. J., and Fitzpatrick, P. F. (1996) Characterization of the
active site iron in tyrosine hydroxylase: Redox states of the iron, J. Biol. Chem.
271, 24395-24400.
81. Fitzpatrick, P. F. (1999) The tetrahydropterin-dependent amino acid
hydroxylases, Ann. Rev. Biochem. 68, 355-381.
82. Sutherland, C., Alterio, J., Campbell, D. G., Le Bourdelles, B., Mallet, J., Haavik,
J., and Cohen, P. (1993) Phosphorylation and activation of human tyrosine
hydroxylase in vitro by mitogen-activated protein (MAP) kinase and MAP-
kinase-activated kinases 1 and 2, Eur. J. Biochem. 217, 715-722.
83. Vulliet, P. R., Hall, F. L., Mitchell, J. P., and Hardie, D. G. (1989) Identification
of a novel proline-directed serine/threonine protein kinase in rat
pheochromocytoma, J. Biol. Chem. 264, 16292-16298.
84. Dunkley, P. R., Bobrovskaya, L., Graham, M. E., von Nagy-Felsobuki, E. I., and
Dickson, P. W. (2004) Tyrosine hydroxylase phosphorylation: Regulation and
consequences, J Neurochem 91, 1025-1043.
85. Campbell, D. G., Hardie, D. G., and Vulliet, P. R. (1986) Identification of four
phosphorylation sites in the N-terminal region of tyrosine hydroxylase, J. Biol.
Chem. 261, 10489-10492.
86. Bevilaqua, L. R. M., Graham, M. E., Dunkley, P. R., von Nagy-Felsobuki, E. I.,
and Dickson, P. W. (2001) Phosphorylation of Ser19 alters the conformation of
tyrosine hydroxylase to increase the rate of phosphorylation of Ser40, J. Biol.
Chem. 276, 40411-40416.
134
87. McCulloch, R. I., and Fitzpatrick, P. F. (1999) Limited proteolysis of tyrosine
hydroxylase identifies residues 33-50 as conformationally sensitive to
phosphorylation state and dopamine binding, Arch. Biochem. Biophys. 367, 143-
145.
88. Ramsey, A. J., and Fitzpatrick, P. F. (1998) Effects of phosphorylation of serine
40 of tyrosine hydroxylase on binding of catecholamines: Evidence for a novel
regulatory mechanism, Biochemistry 37, 8980-8986.
89. Abate, C., and Joh, T. H. (1991) Limited proteolysis of rat brain tyrosine
hydroxylase defines an N-terminal region required for regulation of cofactor
binding and directing substrate specificity, J. Mol. Neurosci. 2, 203-215.
90. Ramsey, A. J., and Fitzpatrick, P. F. (2000) Effects of phosphorylation on
binding of catecholamines to tyrosine hydroxylase: Specificity and
thermodynamics, Biochemistry 39, 773-778.
91. Kuczenski, R., Segal, D. S., and Mandell, A. J. (1975) Regional and subcellular
distribution and kinetic properties of rat brain choline acetyltransferase--some
functional considerations, J Neurochem 24, 39-45.
92. Lloyd, T., and Kaufman, S. (1974) The stimulation of partially purified bovine
caudate tyrosine hydroxylase by phosphatidyl-L-serine,
Biochem.Biophys.Res.Commun. 59, 1262-1269.
93. Katz, I. R., Lloyd, T., and Kaufman, S. (1976) Studies on phenylalanine and
tyrosine hydroxylation by rat brain tyrosine hydroxylase, Biochim. Biophys. Acta.
445, 567-578.
135
94. Daubner, S. C., and Piper, M. M. (1995) Deletion mutants of tyrosine
hydroxylase identify a region critical for heparin binding, Protein Sci. 4, 538-541.
95. Neckameyer, W. S., and White, K. (1992) A single locus encodes both
phenylalanine hydroxylase and tryptophan hydroxylase activities in Drosophila,
J. Biol. Chem. 267, 4199-4206.
96. Gahn, L. G., and Roskoski, R., Jr. (1993) Tyrosine hydroxylase activity and
entrinsic fluorescence changes produced by polyanions, Biochem. J. 295, 189-
194.
97. Frantom, P. A., Seravalli, J., Ragsdale, S. W., and Fitzpatrick, P. F. (2006)
Reduction and oxidation of the active site iron in tyrosine hydroxylase: Kinetics
and specificity, Biochemistry 45, 2372-2379.
98. Fitzpatrick, P. F. (1991) Studies of the rate-limiting step in the tyrosine
hydroxylase reaction:  Alternate substrates, solvent isotope effects, and transition
state analogs, Biochemistry 30, 6386-6391.
99. Daubner, S. C., Hillas, P. J., and Fitzpatrick, P. F. (1997) Characterization of
chimeric pterin dependent hydroxylases: Contributions of the regulatory domains
of tyrosine and phenylalanine hydroxylase to substrate specificity, Biochemistry
36, 11574-11582.
100. Davis, M. D., and Kaufman, S. (1989) Evidence for the formation of the 4a-
carbinolamine during the tyrosine-dependent oxidation of tetrahydrobiopterin by
rat liver phenylalanine hydroxylase, J. Biol. Chem. 264, 8585-8596.
136
101. Moran, G. R., Derecskei-Kovacs, A., Hillas, P. J., and Fitzpatrick, P. F. (2000)
On the catalytic mechanism of tryptophan hydroxylase, J. Am. Chem. Soc. 122,
4535-4541.
102. Eser, B. E., Barr, E. W., Frantom, P. A., Saleh, L., Bollinger, J. M., Jr., Krebs, C.,
and Fitzpatrick, P. F. (2007) Direct spectroscopic evidence for a high-spin Fe(IV)
intermediate in tyrosine hydroxylase, J. Am. Chem. Soc. 129, 11334-11335.
103. Hillas, P. J., and Fitzpatrick, P. F. (1996) A mechanism for hydroxylation by
tyrosine hydroxylase based on partitioning of substituted phenylalanines,
Biochemistry 35, 6969-6975.
104. Eser, B. E., and Fitzpatrick, P. F. (2010) Measurement of intrinsic rate constants
in the tyrosine hydroxylase reaction, Biochemistry 49, 645-652.
105. Hirsch, E., Graybiel, A. M., and Agid, Y. A. (1988) Melanized dopaminergic
neurons are differentially susceptible to degeneration in Parkinson's disease,
Nature 334, 345-348.
106. Haavik, J., and Toska, K. (1998) Tyrosine hydroxylase and Parkinson's disease,
Mol. Neurobiol. 16, 285-309.
107. Haavik, J. (1997) L-DOPA is a substrate for tyrosine hydroxylase, J. Neurochem.
69, 1720-1728.
108. Mockus, S. M., and Vrana, K. E. (1998) Advances in the molecular
characterization of tryptophan hydroxylase, J. Mol. Neurosci. 10, 163-179.
137
109. Miguez, J. M., Simonneaux, V., and Pevet, P. (1997) The role of the intracellular
and extracellular serotonin in the regulation of melatonin production in rat
pinealocytes, J. Pineal. Res. 23, 63-71.
110. Walther, D. J., Peter, J., Bashammakh, S., Hörtnagl, H., Voits, M., Fink, H., and
Bader, M. (2003) Synthesis of serotonin by a second tryptophan hydroxylase
isoform, Science 299, 76.
111. Walther, D. J., and Bader, M. (2003) A unique central tryptophan hydroxylase
isoform, Biochemical Pharmacology 66, 1673-1680.
112. Patel, P. D., Pontrello, C., and Burke, S. (2004) Robust and tissue-specific
expression of TPH2 versus TPH1 in rat raphe and pineal gland, Biol. Psychiatry
55, 428-433.
113. Lovenberg, W., Jequier, E., and Sjoerdsma, A. (1968) Tryptophan hydroxylation
in mammalian systems, Adv. Pharmacol. 6, 21-36.
114. Hasegawa, H., Yanagisawa, M., Inoue, F., Yanaihara, N., and Ichiyama, A.
(1987) Demonstration of non-neural tryptophan 5-mono-oxygenase in mouse
intestinal mucosa, Biochem J 248, 501-509.
115. Zhang, X., Beaulieu, J. M., Sotnikova, T. D., Gainetdinov, R. R., and Caron, M.
G. (2004) Tryptophan hydroxylase-2 controls brain serotonin synthesis, Science
305, 217.
116. Darmon, M. C., Guibert, B., Leviel, V., Ehret, M., Maitre, M., and Mallet, J.
(1988) Sequence of two mRNAs encoding active rat tryptophan hydroxylase, J.
Neurochem. 51, 312-316.
138
117. Grenett, H. E., Ledley, F. D., Reed, L. L., and Woo, S. L. C. (1987) Full-length
cDNA for rabbit tryptophan hydroxylase: Functional domains and evolution of
aromatic amino acid hydroxylases, Proc. Natl. Acad. Sci. 84, 5530-5534.
118. Daubner, S. C., and Fitzpatrick, P. F. (1993) Lysine241 of tyrosine hydroxylase
is not required for binding of tetrahydrobiopterin substrate, Arch. Biochem.
Biophys. 302, 455-460.
119. Windahl, M. S., Petersen, C. R., Christensen, H. E., and Harris, P. (2008) Crystal
structure of tryptophan hydroxylase with bound amino acid substrate,
Biochemistry 47, 12087-12094.
120. Ehret, M., Cash, C. D., Hamon, M., and Maitre, M. (1989) Formal demonstration
of the phosphorylation of rat brain tryptophan hydroxylase by Ca2+/calmodulin-
dependent protein kinase, J. Neurochem. 52, 1886-1891.
121. Makita, Y., Okuno, S., and Fujisawa, H. (1990) Involvement of activator protein
in the activation of tryptophan hydroxylase by cAMP-dependent protein kinase,
FEBS Letts. 268, 185-188.
122. Kuhn, D. M., Arthur, R., Jr., and States, J. C. (1997) Phosphorylation and
activation of brain tryptophan hydroxylase: Identification of serine-58 as a
substrate site for protein kinase A, J. Neurochem. 68, 2220-2223.
123. Banik, U., Wang, G. A., Wagner, P. D., and Kaufman, S. (1997) Interaction of
phosphorylated tryptophan hydroxylase with 14-3-3 proteins, J. Biol. Chem. 272,
26219-26225.
139
124. Furukawa, Y., Ikuta, N., Omata, S., Yamauchi, T., Isobe, T., and Ichimura, T.
(1993) Demonstration of the phosphorylation-dependent interaction of
tryptophan hydroxylase with the 14-3-3 protein, Biochem. Biophys. Res.
Commun. 194, 144-149.
125. Moran, G. R., Daubner, S. C., and Fitzpatrick, P. F. (1998) Expression and
characterization of the catalytic core of tryptophan hydroxylase, J. Biol. Chem.
273, 12259-12266.
126. Joh T. H., H. O., and Abate C. (1986) Phenylalanine hydroxylase, tyrosine
hydroxylase and tryptophan hydroxylase, in Neuromethods Series 1:
Neurochemistry, Neurotransmitter Enzymes (Boulton A. A., Baker G. B., and Yu
P. H., Eds.), pp.1-32, Humana, Clifton NJ.
127. Johansen, P. A., Wolf, W. A., and Kuhn, D. M. (1991) Inhibition of tryptophan
hydroxylase by benserazide and other catechols, Biochem. Pharmacol. 41, 625-
628.
128. Kuhn, D. M., and Geddes, T. J. (1999) Peroxynitrite inactivates tryptophan
hydroxylase via sulfhydryl oxidation. Coincident nitration of enzyme tyrosyl
residues has minimal impact on catalytic activity, J. Biol. Chem. 274, 29726-
29732.
129. Fitzpatrick, P. F. (2000) The aromatic amino acid hydroxylases, in Advances in
Enzymology and Related Areas of Molecular Biology (Purich, D. L., Ed.), pp
235-294, John Wiley & Sons, Inc., New York.
140
130. Moran, G. R., Phillips, R. S., and Fitzpatrick, P. F. (1999) The influence of steric
bulk and electrostatics on the hydroxylation regiospecificity of tryptophan
hydroxylase: Characterization of methyltryptophans and azatryptophans as
substrates, Biochemistry 38, 16283-16289.
131. McKinney, J., Teigen, K., Frøystein, N. A., Salaün, C., Knappskog, P. M.,
Haavik, J., and Martínez, A. (2001) Conformation of the substrate and pterin
cofactor bound to human tryptophan hydroxylase. Important role of Phe313 in
substrate specificity, Biochemistry 40, 15591-15601.
132. Daubner, S. C., Moran, G. R., and Fitzpatrick, P. F. (2002) Role of tryptophan
hydroxylase Phe313 in determining substrate specificity, Biochem. Biophys. Res.
Commun. 292, 639-641.
133. McCulloch, R. I., Daubner, S. C., and Fitzpatrick, P. F. (2001) Effects of
substitution at serine 40 of tyrosine hydroxylase on catecholamine binding,
Biochemistry 40, 7273-7278.
134. Eisensmith, R. C., and Woo, S. L. C. (1991) Phenylketonuria and the
phenylalanine hydroxylase gene, Mol. Biol. Med. 8, 3-18.
135. Nakata, H., and Fujisawa, H. (1982) Tryptophan 5-monooxygenase from mouse
mastocytoma P815 a simple purification and general properties, Eur. J. Biochem.
124, 595-601.
136. Okuno, S., and Fujisawa, H. (1982) Purification and some properties of tyrosine
3-monooxygenase from rat adrenal, Eur. J. Biochem. 122, 49-55.
141
137. Fitzpatrick, P. F., Chlumsky, L. J., Daubner, S. C., and O'Malley, K. L. (1990)
Expression of rat tyrosine hydroxylase in insect tissue culture cells and
purification and characterization of the cloned enzyme, J. Biol. Chem. 265, 2042-
2047.
138. Wang, L., Erlandsen, H., Haavik, J., Knappskog, P. M., and Stevens, R. C. (2002)
Three-dimensional structure of human tryptophan hydroxylase and its
implications for the biosynthesis of the neurotransmitters serotonin and
melatonin, Biochemistry 41, 12569-12574.
139. Pavon, J. A., and Fitzpatrick, P. F. (2006) Insights into the catalytic mechanisms
of phenylalanine and tryptophan hydroxylase from kinetic isotope effects on
aromatic hydroxylation, Biochemistry 45, 11030-11037.
140. Pavon, J. A., and Fitzpatrick, P. F. (2005) Intrinsic isotope effects on benzylic
hydroxylation by the aromatic amino acid hydroxylases: Evidence for hydrogen
tunneling, coupled motion, and similar reactivities, J. Am. Chem. Soc. 127,
16414-16415.
141. Kaufman, S., and Mason, K. (1982) Specificity of amino acids as activators and
substrates for phenylalanine hydroxylase, J. Biol. Chem. 257, 14667-14678.
142. Koehntop, K. D., Emerson, J. P., and Que, L., Jr. (2005) The 2-His-1-carboxylate
facial triad: A versatile platform for dioxygen activation by mononuclear non-
heme iron(II) enzymes, J. Biol. Inorg. Chem. 10, 87-93.
142
143. Ramsey, A. J., Daubner, S. C., Ehrlich, J. I., and Fitzpatrick, P. F. (1995)
Identification of iron ligands in tyrosine hydroxylase by mutagenesis of
conserved histidinyl residues, Protein Sci 4, 2082-2086.
144. Gibbs, B. S., Wojchowski, D., and Benkovic, S. J. (1993) Expression of rat liver
phenylalanine hydroxylase in insect cells and site-directed mutagenesis of
putative non-heme iron-binding sites, J. Biol. Chem. 268, 8046-8052.
145. Fitzpatrick, P. F., Ralph, E. C., Ellis, H. R., Willmon, O. J., and Daubner, S. C.
(2003) Characterization of metal ligand mutants of tyrosine hydroxylase: Insights
into the plasticity of a 2-histidine-1-carboxylate triad, Biochemistry 42, 2081-
2088.
146. Shiman, R., Jones, S. H., and Gray, D. W. (1990) Mechanism of phenylalanine
regulation of phenylalanine hydroxylase, J. Biol. Chem. 265, 11633-11642.
147. Fitzpatrick, P. F. (1994) Kinetic isotope effects on hydroxylation of ring-
deuterated phenylalanines by tyrosine hydroxylase provide evidence against
partitioning of an arene oxide intermediate, J. Am. Chem. Soc. 116, 1133-1134.
148. Frantom, P. A., Pongdee, R., Sulikowski, G. A., and Fitzpatrick, P. F. (2002)
Intrinsic deuterium isotope effects on benzylic hydroxylation by tyrosine
hydroxylase, J. Am. Chem. Soc. 124, 4202-4203.
149. Martinez, A., Abeygunawardana, C., Haavik, J., Flatmark, T., and Mildvan, A. S.
(1993) Conformation and interaction of phenylalanine with divalent cation at the
active site of human recombinant tyrosine hydroxylase as determined by proton
NMR, Biochemistry 32, 6381-6390.
143
150. Daubner, S. C., Hillas, P. J., and Fitzpatrick, P. F. (1997) Expression and
characterization of the catalytic domain of human phenylalanine hydroxylase,
Arch. Biochem. Biophys. 348, 295-302.
151. Kemsley, J. N., Mitic, N., Zaleski, K. L., Caradonna, J. P., and Solomon, E. I.
(1999) Circular dichroism and magnetic circular dichroism spectroscopy of the
catalytically competent ferrous active site of phenylalanine hydroxylase and its
interaction with pterin cofactor, J. Am. Chem. Soc. 121, 1528-1536.
152. Grzyska, P. T., Müller, T. A., Campbell, M. G., and Hausinger, R. P. (2007)
Metal ligand substitution and evidence for quinone formation in taurine α-
ketoglutarate dioxygenase, J. Inorg. Biochem. 101, 797-808.
153. Kaufman, S. (1983) Phenylketonuria and its variants, Adv. Hum. Genet. 13: 217-
297.
154. Phillips, R. S., and Kaufman, S. (1984) Ligand effects on the phosphorylation
state of hepatic phenylalanine hydroxylase, J. Biol. Chem. 259, 2474-2479.
155. Phillips, R. S., Iwaki, M., and Kaufman, S. (1983) Ligand effects on the limited
proteolysis of phenylalanine hydroxylase: Evidence for multiple conformational
states, Biochem. Biophys. Res. Commun. 110, 919-925.
156. Flatmark, T., Stokka, A.J., and Berge, S.V. (2001) Use of surface plasmon
resonance for real-time measurements of the global conformational transition in
human phenylalanine hydroxylase in response to substrate binding and catalytic
activation, Anal. Biochem. 294, 95-101.
144
157. Horne, J., Jennings, I. G., Teh, T., Gooley, P. R., and Kobe, B. (2002) Structural
characterization of the N-terminal autoregulatory sequence of phenylalanine
hydroxylase, Protein Sci. 11, 2041-2047.
158. Flatmark, T., and Stevens, R. C. (1999) Structural insight into the aromatic
amino acid hydroxylases and their disease-related mutant forms, Chem. Rev. 99,
2137-2160.
159. Døskeland, A. P., Døskeland, S. O., Ogreid, D., and Flatmark, T. (1984) The
effect of ligands of phenylalanine 4-monooxygenase on the cAMP-dependent
phosphorylation of the enzyme, J. Biol. Chem. 259, 11242-11248.
160. Miranda, F. F., Teigen, K., Thórólfsson, M., Svebak, R. M., Knappskog, P. M.,
Flatmark, T., and Martínez, A. (2002) Phosphorylation and mutations of Ser16 in
human phenylalanine hydroxylase, J. Biol. Chem. 277, 40937-40943.
161. Miranda, F. F., Thórólfsson, M., Teigen, K., Sanchez-Ruiz, J. M., and Martínez,
A. (2004) Structural and stability effects of phosphorylation: Localized structural
changes in phenylalanine hydroxylase, Protein Sci. 13, 1219-1226.
162. Yan, X., Watson, J., Ho, P. S., and Deinzer, M. L. (2004) Mass spectrometric
approaches using electrospray ionization charge states and hydrogen-deuterium
exchange for determining protein structures and their conformational changes,
Mol. Cell. Proteomics 3, 10-23.
163. Maier, C. S., and Deinzer, M. L. (2005) Protein conformations, interactions, and
H/D exchange, Methods Enzymol. 402, 312-360.
145
164. Li, J., and Fitzpatrick, P. F. (2008) Characterization of metal ligand mutants of
phenylalanine hydroxylase: Insights into the plasticity of a 2-histidine-1-
carboxylate triad, Arch. Biochem. Biophys. 475, 164-168.
165. Pavon, J. A., and Fitzpatrick, P. F. (2009) Demonstration of a peroxide shunt in
the tetrahydropterin-dependent aromatic amino acid monooxygenases, J. Am.
Chem. Soc. 131, 4582–4583.
166. Daubner, S. C., and Fitzpatrick, P. F. (1999) Site-directed mutants of charged
residues in the active site of tyrosine hydroxylase, Biochemistry 38, 4448-4454.
167. Flockhart, D. A., and Corbin, J. D. (1984) Preparation of the catalytic subunit of
cAMP-dependent protein kinase, in Brain Receptor Methodologies, Part A
(Maranos, P. J., Campbell, I. C., and Cohen, R. M., Eds.), pp 209-215, Academic
Press, New York.
168. Royo, M., and Daubner, S. C. (2006) Kinetics of regulatory serine variants of
tyrosine hydroxylase with cyclic AMP-dependent protein kinase and
extracellular signal-regulated protein kinase 2, Biochim. Biophys. Acta. 1764,
786-792.
169. Weis, D. D., Engen, J. R., and Kass, I. J. (2006) Semi-automated data processing
of hydrogen exchange mass spectra using HX-Express, J. Am. Soc. Mass
Spectrom. 17, 1700-1703.
170. Chehin, R., Thorolfsson, M., Knappskog, P. M., Martinez, A., Flatmark, T.,
Arrondo, J. L., and Muga, A. (1998) Domain structure and stability of human
146
phenylalanine hydroxylase inferred from infrared spectroscopy, FEBS Lett. 422,
225-230.
171. Andersen, O. A., Flatmark, T., and Hough, E. (2002) Crystal structure of the
ternary complex of the catalytic domain of human phenylalanine hydroxylase
with tetrahydrobiopterin and 3-(2-thienyl)-L-alanine, and its implications for the
mechanism of catalysis and substrate activation., J. Mol. Biol. 320, 1095-1108.
172. Thórólfsson, M., Teigen, K., and Martínez, A. (2003) Activation of
phenylalanine hydroxylase: Effect of substitutions at Arg68 and Cys237,
Biochemistry 42, 3419-3428.
173. Kaufman, S. (1971) The phenylalanine hydroxylating system from mammalian
liver, in Advances in Enzymology (Alton Meister, Ed.), pp 245-316, Interscience
Publishers, New York.
174. Kaufman, S. (1993) The phenylalanine hydroxylating system, Adv. Enzymol.
Relat. Areas. Mol. Biol. 67, 77-264.
175. Kappock, T. J., and Caradonna, J. P. (1996) Pterin-dependent amino acid
hydroxylases, Chem. Rev. 96, 2659-2756.
176. Stone, A. L. (1980) Studies on a molecular basis for the heparin-induced
regulation of enzymatic activity of mouse striatal tyrosine hydroxylase in vitro.
Inhibition of heparin activation and of the enzyme by poly-L-lysyltyrosine and
poly-L-lysylphenylalanine and their constituent peptides, J. Neurochem. 35,
1137-1150.
147
177. Studier, F. W. (2005) Protein production by auto-induction in high-density
shaking cultures, Protein Expr. Purif. 41, 207-234.
178. Cornilescu, G., Delaglio, F., and Bax, A. (1999) Protein backbone angle
restraints from searching a database for chemical shift and sequence homology, J.
Biomol. NMR 13, 289-302.
179. Kaufman, S., and Mason, K. (1982) Specificity of amino acids as activators and
substrates for phenylalanine hydroxylase, J. Biol. Chem. 257, 14667-14678.
148
VITA
Jun Li received her Bachelor of Science degree in basic medical sciences from
Peking University Health Science Center in 2003. She entered the biochemistry and
biophysics program at Texas A&M University in September, 2004. In May of 2005, she
joined the laboratory of Dr. Paul Fitzpatrick to investigate the structural basis of catalytis
and regulation of phenylalanine hydroxylase. Dr. Li may be reached at Department of
Biochemistry and Biophysics, Texas A&M University, 2128 TAMU, College Station,
TX 77843. Her email is sherrylijcn@hotmail.com.
